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ABSTRACT
Petty, Douglas. Characterizing the Susceptibility and Type I Interferon Response
of Primary Mammalian Cells During Zika Virus Infection. Unpublished
Master of Science thesis, University of Northern Colorado, 2019
Zika virus (ZIKV), a member of the genus Flavivirus, has become a major
public health concern since 2007. During the most recent 2015 outbreak, ZIKV
rapidly spread from South America to over 84 countries and territories across the
world in two years. ZIKV has also been associated with previously
uncharacterized neurological manifestations during the 2013 and 2015
outbreaks. The novel manifestations include Guillain-Barré Syndrome (GBS) in
adults and Congenital Zika Syndrome (CZS) in newborns. GBS is a progressive
paralysis caused by damage to the peripheral nervous system; while CZS is an
all-encompassing term for the severe neurological and developmental
complications observed in newborns infected with ZIKV in utero. The exceptional
rate of spread and unique neurological involvement observed during recent
outbreaks has established a significant demand to expand knowledge on ZIKV
virulence and pathology in humans and other species that could serve as
disease models. To date, only three mammalian species: the rhesus macaque
(Macaca mulatta), guinea pig (Cavia porcellus), and laboratory mouse (Mus
musculus) have been employed to study ZIKV pathology. Of the three
aforementioned species, the most commonly utilized model for ZIKV research is
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a genetically-modified Type I Interferon (IFN) deficient laboratory mouse. Use of
this model provides utility by recapitulating human-like disease; however, the
host immune response of an immunodeficient animal does not accurately reflect
an immunocompetent human immune response. The drawbacks created by the
use of immunodeficient animal necessitate the development of a model where
disease and the host immune response mirror human infections. Therefore, the
current study looks to supplement the lack of ZIKV research across diverse
species and provide the pilot data for justifying further research of the selected
species as an immunocompetent animal model. This project examined ZIKV
susceptibility and the host cell response of three primary cell culture types
derived from less-conventional, yet immunocompetent, models of disease
resistance or pathology; the deer mouse (Peromyscus maniculatus), Jamaican
fruit bats (Artibeus jamaicensis) and Syrian golden hamster (Mesocricetus
auratus). In the current study, we show that primary cell cultures derived from all
three animal models are susceptibility to ZIKV infection. Between the three
selected animal models, primary cell cultures from Jamaican fruit bats and Syrian
golden hamsters demonstrated the highest permissibility to ZIKV replication and
viral shedding. We also provide insight into the host cell Type I IFN immune
response by elucidating the differential regulation of JAK1, STAT1, Oas1b and
ISG15 steady state mRNA levels in response to ZIKV infection. As a whole, our
findings supplement the lack of information of ZIKV research across a diversity of
species and provides the pilot data required to warrant further investigation into
all three species as immunocompetent ZIKV animal models.

iv

ACKNOWLEDGEMENTS
I would like to start by thanking my advisor, Dr. Ann Hawkinson for her
constant support, guidance, and friendship. From the first day that I started as a
UNCO graduate student, she has always been there to help me through any
obstacle that I faced. It has truly been an honor to work in her lab, and I will never
forget all of the fond memories of walking our dogs together and hanging out in
the backyard during the summers. You taught me so much in the classroom and
in the lab, and helped make me into the researcher I am today. I can never thank
you enough for all that you have done for me. With the utmost sincerity, thank
you for being such an amazing and wonderful advisor and friend.
I would also like to thank my committee members, Dr. Patrick Burns and
Dr. Nicholas Pullen for their guidance. Dr. Burns was an invaluable contributor to
my project and he was an incredible mentor throughout my graduate career at
the University of Northern Colorado. Dr. Burns was instrumental in the success of
my research and his guidance allowed me to overcome obstacles that would
never have been possible without him. He is an exceptional researcher/mentor
and an even better friend. It has truly been a privilege to work alongside him in
the lab, and I am very grateful to call him a friend. Thank you Dr. Burns for your
patience, kindness, and remarkable aptitude as a teacher. I would like to thank
Dr. Pullen for always providing insight into the immunology side of my research
and for debating with Dr. Burns about IFNt at all of our committee meetings.

v

Your light-hearted attitude, attention to detail, and depth of knowledge in biology
was instrumental in my success. Thank you for your contributions throughout the
development and completion of my thesis project.
I would like to thank my lab partner and close friend, Tyler Sherman, for
his guidance, insight, and assistance throughout my thesis project. He has
always been there to help at any point during my time at the University of
Northern Colorado and I am eternally grateful for everything that he has done for
me. He is an brilliant researcher and an extraordinary friend. I know that he will
change the world for the better, and I look forward to many more years of being
his friend.
I would like to thank my significant other, Olivia Gilpin, for her unwavering
support throughout this entire endeavor. She has supported me through the ups
and downs that I faced during this project with unyielding support, and I cannot
express enough how thankful I am to have her in my life. I would have never
been able to complete this without your support. Thank you for all that you have
done and thank you for always being there for me.
I would like to thank my parents, Jack and Becky Petty, for their support
from afar throughout my time as graduate student. I owe an immeasurable
amount of thanks to them for raising me and supporting me throughout my life. I
am proud to be your son, and I can never thank you enough for all that you have
done for me. Thank you for helping make me into the person I am today.
I would also like to thank the Hawkinson lab undergraduates, Mykee Cain
and Jordan Davenport, for their invaluable help on this project. A special thanks

vi

to Mykee for completing the viral titer assays. Additionally, I would like to thank
the University of Northern Colorado School Graduate school and school of
Biological Sciences. Thank you to the NHS and GSA for funding my research
and to the University of Northern Colorado’s graduate school for the funding they
provided to the Hawkinson lab.

vii

TABLE OF CONTENTS
CHAPTER
I.

INTRODUCTION AND REVIEW OF LITERATURE…….……….………... 1
Flaviviruses
Structure and Replication
Flavivirus Vaccines
History/Epidemiology of Zika Virus
Zika Virus Isolates
Zika Virus Transmission
Novel Neurological Involvement
Zika Virus Receptor and Cell Tropism
Immune Evasion of Zika Virus
Current Zika Virus Animal Model
Novel Animal Models and Primary Cell Lines
Specific Aims
Chapter Summary

II.

METHODOLOGY…………………………………….……………………… 42
Purpose of the Study
Establishing Primary Cell Lines
Primary Pulmonary Cell Cultures
Primary Kidney Cell Cultures
Primary Hepatocyte Cell Cultures
Stock Virus
Experimental Infections
Sample Collection
Ribonucleic Acid Extraction and Detection
of Viral Ribonucleic Acid
Viral Titer Assay
Cellular Ribonucleic Acid Extraction and Examination of
Type I Interferon Associated Genes
Statistical Analysis of Type I Interferon Associated
Immune Gene Expression

III.

RESULTS ..………………………………………………………………….. 67
Establishment of Primary Cell Lines
Viral Titer of Cell Culture Suspension
Detection of Viral Ribonucleic Acid in 72 hour Cell Pellet
and Suspension Samples

viii

Examination of Type I IF Associated Genes
IV.

DISCUSSION & CONCLUSIONS.…………………………...…………...
Discussion
Conclusions
REFERENCES…………………………………………………………….

88

100

APPENDIX
A. List of Acronyms…………………………………………………………. 117
B. Institutional Animal Care and Use Committee Approval……………. 121

ix

LIST OF TABLES
2.1 Thermocycler programs for PCR analysis………………………………..

61

2.2 A list of the primer sequences and PCR product size
for all eight primer sets…………………………………………….............. 62
3.1 A visual representation of the established primary cell lines…………… 68
3.2 A comparison of viral RNA and infectious virus
detected in suspension samples……..…………………………………….. 75

x

LIST OF FIGURES
1.1 An overview of the flavivirus replication cycle…………………………….

6

1.2 Detection of viral RNA by Pattern Recognition Receptors………...…… 24
1.3 The Type I Interferon pathway………………….…………………………. 26
2.1 Step by step images of the two-step perfusion method
for the isolation of primary hepatocytes…………………………………… 53
2.2 A comparison of a non-infected Vero E-6 well with a
ZIKV infected well…………………………………………………………... 58
2.3 A comparison between the original immune gene PCR products
gel image from bat 7’s hepatocyte cell pellet RNA and
the FIJI converted image…………………………………………………… 64
2.4 The plotted lanes from DM 6’s b-actin densities in
hepatocyte cultures………………………………………………...…..….. 65
3.1 Timeline images of primary deer mouse hepatocytes from
initial isolation to day 12 post inoculation…………………………..…….. 69
3.2 Gel image of ZIKV treated cell pellet samples…………………………... 71
3.3 Gel image of ZIKV treated Bat cell suspension samples………………. 73
3.4 Gel image of re-run false positive negative controls……………………. 74
3.5 (a-d) Expression levels of JAK1, STAT1, ISG15 and Oas1b
for Deer mouse samples…………………………………………………... 78
3.6 (a-c) Expression levels of JAK1, STAT1, and ISG15 for Jamaican
fruit bat samples……………………………………………………………... 83
3.7 Expression levels of JAK1, STAT1, and Oas1b for Syrian
golden hamster samples…………………………………………............... 87

xi

CHAPTER I
INTRODUCTION AND REVIEW OF LITERATURE
Flaviviruses
The Flavivirus genus is one of four genera belonging to the family
Flaviviridae. The genus is a widely diverse group comprised of 53 recognized
viruses with over 40 members cited as human pathogens [1, 2]. Within the
Flavivirus genus, members are grouped into three subgroups reflecting the virusvector-transmission route. The subgroups include arthropod-borne viruses
(arboviruses), insect specific viruses, and no known vector viruses [1]. The
arbovirus subgroup, which includes ZIKV, is comprised of flaviviruses that are
primarily transmitted by arthropod vectors such as mosquitoes and ticks. Other
notable human pathogens comprising the arbovirus subgroup include yellow
fever virus (YFV), dengue virus (DENV), Japanese encephalitis virus (JEV), Tickborne encephalitis virus (TBEV), and West Nile Virus (WNV) [3, 4]. Human
infections with arboviruses of the flavivirus genus can manifest in a wide range of
clinical symptoms and complications ranging from an asymptomatic or mild
febrile illness, to severe hemorrhagic fever, encephalitis, and developmental
abnormalities in children [5, 6]. Regarding epidemiology, the Flavivirus genus is
the most relevant genus of viruses regarding the state of public health in tropical
and subtropical regions of the world due to the burden generated by DENV,
WNV, and YFV. The World Health Organization has estimated that DENV’s
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endemic range covers over 100 countries and 250-530 million cases of DENV
infection occur worldwide every year. In 2016, over 3.34 million cases were
reported in the Americas, South East-Asia and the Western Pacific. The Centers
for Disease Control and Prevention also estimates that 100 million people will
have symptomatic DENV infections and 22,000 deaths will occur every year due
to DENV hemorrhagic fever [7, 8]. Between 1999-2018 WNV generated over
50,000 cases in the United States alone. Of the reported WNV cases, 24,657
cases manifested with neurological symptoms and over 2,000 deaths occurred
from WNV infection [9]. Although YFV does not generate a considerable burden
in countries like the U.S., it poses a considerable threat to countries in Africa and
Central and South America. The WHO reports that 40 countries, 27 in Africa and
13 in the Americas, are at high risk for YFV epidemics. In 2013, the lack of prior
immunization in central and east Africa allowed for a major outbreak to occur
resulting in an estimated 84,000-170,000 YFV severe cases and 29,000-60,000
deaths [10]. Unfortunately, the burden to global health posed by these members
of the Flavivirus genus will most likely increase in the oncoming years due to
increasing vector ranges, a lack available vaccines for many of the viruses, and
the scarcity of efficacious therapeutic treatments. The reality of the situation
regarding the flaviviruses prompts a need to elucidate the nature of these viruses
in order to effectively combat the significant threat they pose to the future of
public health.
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Structure and Replication
Flaviviruses are enveloped positive sense Ribonucleic Acid (RNA) viruses
comprised of approximately 11 kilobases containing a single open reading
frame. The single open reading frame is flanked at the 5’ and 3’ end by two short
noncoding regions designated as the untranslated regions [2].The flavivirus life
cycle is initiated by the attachment and entry of a mature virion into a susceptible
host cell via Clathrin-mediated endocytosis. Clathrin-mediated endocytosis is a
trafficking mechanism of the cell typically involved in nutrient uptake and cell
signaling from the cell surface to the interior of the cell. ZIKV, along with other
flaviviruses hijack the endocytic pathway as a means to gain entry into the host
cell [11]. Currently, researchers hypothesize that flaviviruses gain access to a
clathrin coated pit by rolling on the cell surface after loosely interacting with
glycosaminoglycans (GAGs). GAGs are negatively charged low affinity
attachment factors such as heparin sulfate or chondroitin sulfate [11, 12]. The
flavivirus virions will roll on the cell until they come into contact with their
respective entry receptor located within the clathrin-coated pits. After entry
receptor attachment and clathrin-mediated endocytosis, proton pumps in the
cell’s endosomes will generate a drop in pH, which will trigger a conformational
rearrangement of the viral envelope protein (E protein) to allow for fusion of the
viral and endosomal membranes. The fusion of the membranes triggers the
release of the viral capsid into the cytoplasm. Once the viral capsid is in the
cytoplasm, it will un-coat and release the positive sense single stranded RNA
genome. The viral RNA will travel to the endoplasmic reticulum and interact with
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host ribosomes to initiate translation. The flaviviral genome is translated into a
single polyprotein and it is co- and post-transitionally cleaved by host and viral
proteases into three structural and seven nonstructural proteins [4, 13-15]. The
structural proteins include the capsid (C), pre-membrane/membrane (prM/M),
and envelope (E). The C, M, and E proteins form the structural components of a
mature virion, mediate attachment/entry into a cell, and protect the viral genome
outside of the host cell. The non-structural proteins, on the other hand, are
implicated in the replication of the viral genome, virus assembly, polyprotein
processing, and most relevant to the this research project, the modulation of host
cell immune response. The flaviviral non-structural proteins are designated as
the NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 proteins [4, 14, 15].
Along with translation of the viral proteins, the replication of the viral
genome and assembly of progeny virions will occur within invaginations of the
endoplasmic reticulum known as vesicle packets. The vesicle packets are an
important component for evasion of the host immune response early on during
an infection due to their capacity to “hide” the exposed viral RNA from host
immune sensory mechanisms, such as Retinoic acid-inducible gene-I-like
receptors (RLRs) [14, 16]. Within the vesicle packets, the positive sense RNA
genome will initially be transcribed into a negative sense RNA strand by the
RNA-dependent RNA polymerase, NS5, that will be used a template for
transcribing the positive sense RNA genome for the progeny virus. During
transcription, the viral genome will be capped with a methyl guanosine
trisphosphate by NS5 acting as a methyltransferase [17]. Once enough of the E,
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C and prM proteins have been translated, the newly capped viral genome will
interact with C proteins that have aggregated on the cytoplasmic side of the ER
and will bud into the lumen of the ER. The newly formed immature virion will be
covered with prM and E proteins that were present on the lumen side of the ER
[13, 14]. An immature virion is distinguished from a mature virion by the presence
of un-cleaved pre-membrane protein (prM). The presence of the prM protein is
vital during the transit through the secretory pathway, because the prM protein
prevents the E protein from fusing with the ER and Golgi apparatus’ membrane
[17]. As the immature virion makes its way through the Golgi apparatus, the
cellular protease, furin, will cleave the prM protein into pr and M. The cleavage of
the prM protein will generate a confirmation change of the E protein from a
heterodimer with the prM protein to a E protein homodimer. The new
confirmation signifies a fully mature virion that can be transported to the plasma
membrane to be released from the host cell via exocytosis [4, 14-17]. The
released mature virion will have a diameter of ~50 nm, a membrane taken from
the host cell endoplasmic reticulum, and a smooth surface comprised of E
proteins in a herringbone pattern [18]. The mature virion will remain in the
extracellular environment until it makes contact with the receptor of another
susceptible cell, wherein it will be endocytosis and the viral replication process
will commence again. Figure 1.1 displays an overview of the flavivirus life cycle
to help visualize each step of the process.
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Figure 1.1: An overview of the flavivirus replication cycle. (1) The
attachment of a virion to a species-specific entry receptor. (2) The drop in pH
within the host cell endosome mediated by protons being pumped into the
endosome. (3) The drop in pH allows for the viral E protein to fuse with the
endosomal membrane, allowing for the release of the viral RNA into the host cell.
(4/5) The +ssRNA will travel to the endoplasmic reticulum where it is replicated
and translated into the single polyprotein. (6) The newly synthesized +ssRNA
and structural proteins will form an immature virion that will bud out of ER. (7)
The immature virion will traffic through the trans-Golgi network where it will be
cleaved by host cell proteases to transition into a mature virion. (8) The mature
virion traffics to the host cell membrane where it released into the extracellular
space [15].
Flavivirus Vaccines
As of November 2017, commercially available vaccines exist for Dengue
virus (DENV), yellow fever virus (YFV), Japanese encephalitis virus (JEV), West
Nile virus (WNV) and Tick-borne encephalitis virus (TBEV). The vaccines for
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YFV, JEV, TBEV all provide efficacious vaccine protection for human populations
[19]. The YFV vaccine, YFV 17D, is a live attenuated vaccine that was developed
through serial passages of an isolated YFV sample in 1937 by Max Theiler.
Since its development, over 500 million individuals have been vaccinated with
the YFV 17D vaccine and the efficacy has been shown to be 98% effective for at
least 10 years. The most current JEV vaccine, a live attenuated SA-14-14-2
strain, was licensed in 1988 and has been shown to be 88-96% effective [4]. The
TBEV vaccine is a highly purified formalin-inactivated whole virus vaccine. The
vaccine is produced in Western Europe and Russia, and has been shown to be
98% effective at preventing disease for up to 3 years [4, 19].
Dengvaxia, the only licensed DENV vaccine, has had a number of issues
in its application, such as an uncertainty regarding the correlate of protection
over time and against different DENV serotypes. In two phase III clinical trials,
the pooled vaccine efficacy was only 59.2%. The efficacy also varied by
serotype, with a range of 43-76.9 % (DENV serotypes 1-4).The suboptimal
performance by Dengvaxia has prompted researchers to continue to pursue
alternative vaccine candidates that offer a higher confidence of protection in
humans.
Similar to DENV, a vaccine for WNV does exist, but the vaccine is only
available for application in the veterinary field. A formalin-inactivated vaccine has
been developed and licensed in the early 2000’s for preventing WNV disease in
horses. The most promising WNV vaccine for humans, a YFV 17D backbone
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chimeric vaccine expressing WNV antigens, has been shown to induce high titers
of neutralizing antibodies and is currently in Phase III clinical trials [19].
To date, there are still no commercially available vaccines or therapeutic
treatments against ZIKV. The ongoing development of a ZIKV vaccine has
generated over 50 vaccine candidates that are currently undergoing clinical trials
[19-22]. Candidate vaccines in phase I or II of clinical trials include: inactivated
whole viruses, recombinant measles viral vector-based vaccines,
Deoxyribonucleic Acid (DNA) and messenger RNA (mRNA) vaccines, and a
unique mosquito viral vector-based vaccine [22]. According to the World Health
Organization, only two of the aforementioned candidate vaccines have made it to
phase II of clinical trials. The two candidate vaccines include a mRNA vaccine,
mRNA-1325, and a DNA vaccine, VRC-ZKADNA090-00-VP [23]. The mRNA
vaccine, developed by Moderna Therapeutics, is a mRNA vaccine encapsulated
in lipid nanoparticles. Trials with the vaccine have demonstrated complete
protection against ZIKV challenge in AG129 mice (both mother and fetal
progeny) and rhesus macaques. The DNA vaccine, developed by the National
Institute of Allergy and Infectious Disease Vaccine Research Center, expresses
the ZIKV pre-membrane and envelope proteins of the French Polynesia isolate
(H/PF/2013). Previous studies with the vaccine have demonstrated
immunogenicity in mice and monkeys [22]. The progress regarding ZIKV vaccine
development is promising, but there is still a considerable amount of research
and clinical trials required before a commercially available vaccine will be offered.
The current estimate, based on the timelines required for approval of previous
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flaviviral vaccines, puts the licensure of a ZIKV vaccine between 2022-2023 [22].
The United States Food and Drug Administration approved ZIKV vaccine timeline
and lack of efficacious vaccines for WNV and DENV generates a necessity to
better understand flaviviral pathogenesis. Elucidating the vital components of
their pathogenesis would provide insight into avenues for increasing the efficacy
of the vaccines, reducing the timelines required to create effective vaccines, and
aiding in the development of therapeutic treatments.
History/Epidemiology of Zika Virus
Zika virus (ZIKV) was first isolated in 1947 during a routine surveillance for
yellow fever virus. The first isolate, MR766, was isolated from the serum of a
sentinel rhesus macaque in the Zika forest of Uganda. After the initial isolation,
ZIKV was isolated a second time from a pool of Aedes africanus mosquitos
collected in the Zika Forest in 1948 [24].The first reported case of human ZIKV
infection was reported by David Ian Hewitt (D.I.H.) Simpson in Uganda in 1964.
The account written by Simpson himself described the clinical symptoms that he
suffered during the course of the ZIKV infection. He contracted the viral infection
during a surveillance mission to isolate Zika virus from A. africanus between
1962-1963 [25, 26]. Although ZIKV was discovered in 1947, the first major ZIKV
outbreak did not occur until 60 years after the initial isolation. Prior to the first
major outbreak, ZIKV circulated in Africa and Asia generating sporadic cases of
infection. During the 60 year circulation period, only 14 cases of symptomatic
infection were reported in humans [27]. However, serological surveys conducted
in 17 different countries and regions in Africa and Asia indicated a widespread
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distribution of ZIKV. In 1966, the presence of ZIKV in Asia was further confirmed
by isolation from an Aedes aegypti mosquito [24, 28].
In 2007, the first major ZIKV outbreak occurred on Yap Island, a
Federated State of Micronesia. The outbreak was estimated to effect ~73% of the
roughly 7,000 inhabitants of the island. Of the affected population, approximately
18% manifested with clinical symptoms. The clinical symptoms observed during
the outbreak included a mild febrile illness, a maculopapular rash, arthralgia and
conjunctivitis [28, 29]. One year later, the first case of potential ZIKV sexual
transmission was reported. Two American virologists working in southeast
Senegal returned to the U.S. and began suffering from rash, headache, fatigue,
arthralgia, and haematospermia (only one individual). Serological samples taken
from both individuals indicated that the most probable causative agent was Zika
virus. Soon after returning, the wife of one of the virologists also began to suffer
from the same symptoms. Investigation into the route of transmission concluded
that the most probable route was either through saliva or sexual contact. The
subsequent detection of high ZIKV titers and ZIKV RNA in semen has supported
the viability of ZIKV sexual transmission [24].
The second major ZIKV outbreak occurred between 2013 and 2014 on the
French Polynesian islands. During the course of the outbreak, approximately
11% of the population was estimated to have sought out treatment for suspected
ZIKV infections. Although most of the symptomatic cases presented with the
same febrile illness observed in the 2007 outbreak, the defining feature of the
French Polynesian outbreak was the small fraction of severe cases associated
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with Guillain-Barré Syndrome (GBS) [21, 24, 28, 29]. Post-outbreak studies of
epidemiological data revealed that the cases of GBS during the outbreak rose by
a staggering ~20 fold increase [28]. Either shortly after or during the 2014
outbreak, imported cases of ZIKV were reported in New Caledonia, Easter
Island, the Cook islands, Australia, Italy, Japan and Norway [28]. By mid-January
2014, 1,385 laboratory confirmed cases of ZIKV infection on the island of New
Caledonia indicated that ZIKV was spreading and had become endemic on
neighboring islands in the Pacific [24].
In March 2015, seven cases of Reverse Transcriptase-quantitative
Polymerase Chain Reaction (RT-qPCR) confirmed ZIKV infections were reported
in Bahia, Brazil. The confirmed cases were the first reported cases of the most
recent 2015 outbreak. Sequence analysis of the ZIKV envelope protein from an
isolated sample revealed a 99% identity with the 2013 French Polynesian isolate
[24]. Phylogenetic and molecular clock analysis indicate that the outbreak was
initiated by a single introduction of ZIKV into Brazil. Epidemiologist postulate that
the virus was likely brought into the country by a French Polynesian traveler who
had recently stopped at Easter Island [29]. Within one year of the initial isolation,
ZIKV had spread from Bahia to at least 14 states of Brazil. Along with an
exceptional rate of spread, the 2015 outbreak was characterized by an
unforeseen increase of microcephaly cases of newborn infants in regions with
local ZIKV transmission. The presence of microcephaly during the 2015
prompted a retrospective study on the 2007 French Polynesian outbreak
regarding ZIKV associated microcephaly. The study revealed a similar increase
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in the number of cases of microcephaly and other fetal abnormalities that were
observed during the 2013/2014 outbreak [27, 28].
In December 2015, the first case of local ZIKV transmission in a U.S.
territory, Puerto Rico, was reported. Subsequently, two U.S. states, Florida and
Texas, reported autochthonous transmission of ZIKV in 2016 [30]. By November
2016, 48 countries and territories in the Americas had reported autochthonous
transmission of ZIKV [28]. The continual spread and association with fetal
abnormalities prompted the World Health Organization to declare a state of
Public Health Emergency of International Concern from February 1st 2016 to
November 18th 2016 regarding ZIKV [21]. The latest World Health Organization
ZIKV epidemiology situation report, published in July of 2019, reports that ZIKV
has spread to 87 countries and territories across the world with vector borne
ZIKV transmission since the beginning of the 2015 outbreak [31]. Although the
number of reported ZIKV cases have significantly decreased since 2017, there
are still 68 countries on the Centers for Disease Control and Prevention’s travel
notice for risk of ZIKV transmission [32, 33]. The extensive range of ZIKV,
association with severe neurological manifestations, and the World Health
Organization’s declaration of a global health crisis has stimulated novel research
that has supplemented the collective knowledge on ZIKV, but a large number of
questions and issues still remain that must be addressed.
Zika Virus Isolates
During the 60-year period between 1947 and 2007, ZIKV remained
relatively obscure while it circulated in Africa and Asia causing minor outbreaks.
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The continual circulation of ZIKV during the period allowed the virus to diverge
into the two distinct lineages that are recognized today. However, a recent
phylogenetic analysis by Shen et al. has provided evidence for a third lineage.
The proposed lineage would create a spilt in the African lineage into the West
African (Nigerian cluster) and East African (MR766 cluster) lineages [34, 35]. It is
important to note which lineage is being utilized in a study, because previous
research has indicated significant differences in the replication kinetics and
virulence between isolates from different lineages [21, 36].
In a study with Stat2-/- mice, Tripathi et al. compared ZIKV infections with 5
isolates from a range of geographically and temporally relevant origins [21]. The
results of the study indicated that there were considerable differences between
the two distinct lineages. African lineage isolates are generally more virulent with
a rapid onset of severe neurological symptoms in Stat2-/- mice. African strains
also induced a high level of inflammatory cytokines and markers associated with
cellular infiltration in the infected mice. Isolates of the Asian lineage, on the other
hand, were generally less virulent and presented with a delayed onset of
symptoms. However, the delayed onset of symptoms also coincided with a more
prolonged neurological infection [21].
Bowen et al. also arrived at a similar conclusion in a study involving ZIKV
and human dendritic cells (DCs) [37]. Four isolates, 2 of each lineage, were
employed in their study to represent “contemporary and historic” isolates of both
lineages. Results of the study demonstrated that both African and Asian ZIKV
isolates have the same binding efficiencies to human DC’s, but the viral
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replication kinetics and the immune response/suppression were notably different
between the two lineages. The African lineage replicated at a faster rate in the
human DCs with a higher overall magnitude in the viral load during infection
compared to the Asian lineage isolates. As well, human DCs cell death was only
observed in cultures infected with African lineage isolates [37].
Currently, there are over 290 ZIKV isolate genomes available on NCBI. Of
those genomes, 256 were isolated from humans, 36 from mosquitos, and 8 from
Non-Human Primates and cell culture [29]. The PRVABC59 isolate utilized in the
current study belongs to the Asian lineage and was isolated from a patient in
Puerto Rico during the most recent 2015 outbreak. There is a 99.6% nucleotide
sequence homology and 99.9% amino acid homology between the selected
isolate and the initial 2015 isolate from Bahia, Brazil [38]. The PRVABC59
isolate, as with many previous studies, has been chosen for the current study as
the ideal candidate for elucidating information regarding the emerging ZIKV
isolates that have caused the concerning rise in the associated neurological
manifestations, novel modes of transmission, and the alarmingly rapid
dissemination of the virus across the world in less than a year [37, 39-41].
Transmission of Zika Virus
As an arthropod-borne (arbo) virus, ZIKV, is primarily transmitted through
the feeding of hematophagous mosquitos. The two main vectors of ZIKV
transmission are Aedes aegypti and Aedes albopictus. ZIKV has also been
demonstrated to infect and replicate in the midgut and salivary glands of Culex
spp. of mosquitos by Guedes et al., but the findings are still relatively
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controversial and require further evaluation [42]. Aedes aegypti is considered to
be the primary vector of ZIKV, because previous research has demonstrated the
susceptibility of the mosquitos and successful viral isolation from populations of
Aedes aegypti [43]. Aedes aegypti are also thought to have a higher capacity as
a vector because they will primarily bite humans, feed from multiple humans
during a single blood meal, and live in close proximity to humans [28, 44]. Both
species of mosquito are widely distributed throughout tropical and subtropical
regions of the world. Researchers have also noted that the wide distribution of
both mosquitos will likely increase over the next decade due to global warming
into regions previously protected by the limited tropical and subtropical range of
the vectors [45, 46]. The increased range will put more individuals at risk for local
transmission of flaviviruses carried by both vectors including ZIKV, YFV and
DENV.
Non-vector-borne ZIKV transmission has been documented through
multiple routes including sexual transmission, in utero transmission from a
mother to progeny, and transmission of bodily fluids via breast milk or blood
transfusions [24, 28]. Since the first reported cases of potential sexual ZIKV
transmission, cases have revealed that transmission can occur from both sexes.
The highest potential for sexual transmission is estimated to be within the first 12
days after symptom manifestation [47]. Of the potential transmission types, maleto-female transmission has been noted to occur with the highest frequency [28].
In a review of reported cases of sexual transmission, 94% (34 out of 36) of cases
were male-to female, and only 3% (1 case) demonstrated female-to-male
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transmission [47]. In an evaluation of prolonged viral shedding in the male
reproductive tract, viral RNA was detected in semen up to 9 months after the
initial infection. Although evidence shows a prolonged shedding of viral RNA,
levels of infectious virus in semen rapidly decreased during the first 3 months
after the symptomatic phase of the infection [48]. Due to the higher frequency of
males being involved in sexual transmission, the majority of the research
regarding sexual transmission has focused on males. However, reported cases
of ZIKV have demonstrated that viral RNA can be detected up to 37 days in fluid
from the female genital tract [47].
The majority of research regarding female’s capacity to transmit ZIKV has
focused on the vertical transmission from a mother to her progeny. In trans
placental transmission, a pregnant mother with viremia can transmit the ZIKV
through the placenta to her child while in the child is in utero. Interestingly, the
pathway in which the ZIKV is able to infect and gain access to the placenta, and
subsequently the fetus, is still not completely understood. Previous research has
demonstrated that ZIKV isolates in the Asian lineage have the capacity to infect
the human decidua, trophoblasts, and umbilical cord tissues. Access these tissue
is thought to allow for the virus to gain access to the fetus and lead to apoptosis
of chorionic villi, which would result in the breakdown of the fetal blood/nutrient
supply [29, 49, 50]. Conversely, recent studies have demonstrated that primary
human trophoblast cells effectively block ZIKV replication and fetal transmission
via the breakdown of the trophoblast mediated barrier by constitutively
expressing of Type III IFNs (IFNl1) [51, 52]. As an alternative pathway, Quike et
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al. provides evidence for cell-associated transport to the fetal blood supply
through ZIKV susceptible human Hofbauer cells [53]. Therefore, the transmission
of ZIKV to the fetus could be possible without the required breakdown in the
human trophoblast mediated fetal blood supply barrier. The mechanism by which
ZIKV gains access to the fetus from the mother may not be abundantly clear at
this time, but it is apparent that the ZIKV has adapted a unique mechanism for
subverting human reproductive barriers to cause the severe developmental
abnormalities that have been associated with the virus.
Novel Neurological Involvement
The common clinical manifestations of Zika virus infection, known as Zika
fever, include fever, maculopapular rash, arthralgia, myalgia, headache, and
conjunctivitis [21, 54]. The mild febrile has an established incubation period of 314 days with an average of 6 days. The onset of clinical symptoms will typically
occur within one week of inoculation but have also been observed to manifest up
to two weeks after the initial inoculation. Symptomatic infections are self-limiting
and will typically subside after two weeks [55].
Since the 2013 and 2015 outbreaks, ZIKV has also been associated with
novel neurological manifestations that include Guillain Barré Syndrome in adults
and Congenital Zika Virus Syndrome (CZS) in newborns. Guillain Barré
Syndrome, a neurological sequelae of ZIKV infections occurs after
convalescence of the symptoms. Guillain-Barré syndrome is a progressive form
of flaccid paralysis that is caused by autoimmune damage to the myelin sheaths
insulating neurons of the peripheral nervous system [21]. CZS, a term used to
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encompass all of the developmental abnormalities associated with in utero ZIKV
infections, can manifest as a spontaneous abortion, ocular abnormalities,
microcephaly, hydrocephaly, microcephaly, abnormal joint and smooth muscle
development, and intrauterine growth restriction [27, 54].
Zika Virus Receptor and Cell Tropism
ZIKV entry into the host cell is mediated by the interaction between the Nglycan conjugated to the ZIKV E protein (at Asn154) and host cell receptors [11,
56, 57]. However, the specific receptor involved in the interaction is still highly
debated. Due to the extensive list of susceptible cell types, it has been difficult for
researchers to identify a single cell receptor as the main culprit for ZIKV entry.
Therefore, the leading hypothesis is that ZIKV utilizes a broad number of cell
receptors to mediate its capacity to infect multiple different cell lines. In humans,
ZIKV tissue tropism has been observed in neural, ocular, renal, testicular,
uterine, vaginal, and placental tissues. As well, ZIKV has also been detected in
multiple bodily fluids including tears, saliva, semen, cervical mucus, and urine
[58-60]. The following sections will discuss the leading candidates for the
proposed entry cell receptors.
The most predominant candidate in ZIKV entry receptor research is AXL.
AXL or Tyro7 is a member of the TAM family of receptor tyrosine kinases. As a
member of the TAM family, AXL is thought to be involved in cell proliferation,
migration, invasion, and survival signaling for a number of different cell types [61,
62]. AXL has also been shown to be involved in the clearance of apoptotic cells,
regulating innate immunity, and anti-inflammatory pathways [11]. Unlike the
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related TIM receptor counterparts, TAM receptors do not bind directly to viral
glycoproteins. AXL, like other TAM receptors, will indirectly interact with the
glycosylated ZIKV E protein binding site through the mediator protein Gas6.
Relevant cell types expressing AXL in regard to ZIKV infections include: radial
glial cells, astrocytes, microglial cells, endothelial cells, ocular progenitor cells,
Sertoli cells [39, 62, 63].
The basis for implicating AXL as the entry receptor is instigated by a
considerable amount of previous research conducted in primary human cells [25,
62-66]. Liu et al. has demonstrated ZIKV’s association with AXL by blocking the
receptor on human vascular endothelial cells (HUVEC) with an antibody that
recognizes the extracellular portion of AXL. Two ZIKV isolates (MR766 and
PRVABC59) were unable to infect the HUVEC cell cultures after treatment with
the antibody. Along with these finds, the authors also demonstrated that 239T
cells with ectopic expression of AXL were susceptible to ZIKV infection and a
mutation (K567R) that prevents the phosphorylation and signaling of AXL
disrupted ZIKV susceptibility in the 239T cells [65].
In agreement with Liu et al.’s findings, Persuad et al. also demonstrated
that AXL deficient human (malignant) fibroblast cell lines, HT1080, were not
permissive to ZIKV infection. The researchers developed AXL knockout lines of
HT1080 cells with the CRISPR/Cas9 system and experimentally infected them
with increasing Multiplicity of Infections (MOIs) of ZIKV (MR766 isolate). The two
developed HT1080 knockout lines, clones 3-II and 1-1V, were not susceptible to
ZIKV infection at any of the tested MOIs. Conversely, the selected control cell
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line that expressed functional AXL receptors showed ZIKV infection at MOIs of
0.5-10 [66]. The protection against ZIKV infection in AXL negative lines has also
been demonstrated by previous research groups in primary human astrocytes
and sertoli cells, and immortalized microglial cells (CHME3), glioblastoma cells
(U87), and human epithelial cells (HeLa) [63, 66-71].
In contradiction to the findings on AXL’s importance, recent studies have
provided surmounting evidence that AXL is not indispensable for ZIKV [68, 72].
Instead, researchers have proposed that ZIKV will utilize different entry receptors
depending on the cell type in question. In a study focused on ZIKV in skin cells,
Hamel et al. note that DC-SIGN and Tyro3 were mediators for ZIKV entry into
host cells [25, 65]. Hamel’s research group utilized a series of HEK293T cells
expressing DC-SIGN, TIM-1 ,TIM-4 and Tyro3 to determine the importance of the
expressed receptors on ZIKV susceptibility. The researchers found that the cell
lines expressing DC-SIGN and Tyro3 were highly permissive to ZIKV infection
[73]. Tyro3, like AXL, is a TAM receptor that is expressed on a wide range of cell
types. Conversely, DC-SIGN is a significant finding as a ZIKV receptor due to the
receptor’s specific expression on macrophages and immature dendritic cells. In
the typical mode of transmission, a mosquito will transmit the virus through its
saliva via a hematophagous feeding. During the feeding, the virus laden saliva
will be delivered to the dermis and epidermis of the new host. The area around
initial infection site will be full of immune migratory cells like dendritic cells and
macrophages. The close proximity of DC-SIGN expressing cells provides the
perfect opportunity for the virus to not only replicate at the site of entry, but also
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utilize the migratory facet of the immune cells to gain access to the bloodstream
and other tropic tissues [74].
TIM-1 was also shown to mediate ZIKV entry into HEK293T cells, but at a
significantly lower effect in relation to DC-SIGN and Tyro3. Tabata et al.
reinforced these findings by using duramycin to block TIM-1 activity in human
chronic villus explants. Duramycin is phosphatidylethanolamine binding antibiotic
that disrupts membrane function. The antibiotic was previously demonstrated to
disrupt DENV infection through the same TIM-1 blocking mechanism. The results
of the study indicated that duramycin mediated disruption of TIM-1 effectively
blocked ZIKV infection in the explanted placental tissue. TIM-1 is a glycoprotein
that interacts with the phosphotidylserine displayed on a viral membrane [11, 73,
75]. The glycoprotein receptor is expressed on Hofbauer macrophages,
endothelial cells, and cytotrophoblasts [58]. As discussed in the transmission of
ZIKV, the aforementioned cell types are found in the uterus and placental region
of humans. The connection of these reproductive associated cells expressing the
potential entry receptors for ZIKV into placenta and uterine tissue play an
important role in understanding the mechanism ZIKV utilized to generate the
vertical transmission from a mother to her progeny.
Immune Evasion of Zika Virus
The Type I Interferon (IFN) pathway is a vital component of the innate
immune response against viral replication through the induction of a potent
antiviral state in infected cells which is characterized by a halt in RNA and protein
synthesis [76]. Upon entry into the host cell, flaviviruses such as ZIKV will trigger
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the Type I IFN response through the the cell’s detection of pathogen associated
molecular patterns (PAMPs) using pattern recognition receptors (PRRs). PRRs
include innate immune receptors such as Retinoic acid-inducible gene-I-like
receptors (RLR), Toll-like receptors (TLR 1 -10), cGas, IFI16, and many more. Of
the RLRs, RIG-I is considered to be the major cytoplasmic sensor involved in the
initial detection of flaviviruses. MDA5, another RLR, is also involved in flavivirus
detection, but previous research has indicated that MDA5 knockout MEF cells
are still able to efficiently respond to DENV and WNV infections [77-80].
Therefore, MDA5’s Type I IFN response involvement is thought to be more of a
secondary receptor role in response to flavivirus infection.
As members of the RLR family, RIG-I and MDA5 are both DExD/H box
RNA helicases that bind and unwind RNA. The major difference between RIG-I
and MDA5 is their RNA recognition preferences. MDA5 has been shown to
preferentially bind to high molecular dsRNA poly I:C fragments, whereas RIG-I
preferentially binds to shorter 5’ triphosphorylated double stranded and single
stranded RNA fragments. Along with the DExD/H box domain, both RLRs have
two tandem caspase activation and recruitment domains (CARD1 and 2
domains) and a C-terminal repressor domain. After recognizing and binding to
cystosolic viral RNA, RIG-I will alter its confirmation to expose the CARD
domains. The exposed CARD domain permits the interaction of RIG-I with the
Mitochondrial antiviral signaling adapter (MAVS). Association with MAVS (also
known as IPS-1) recruits TANK-binding Kinase 1 (TBK1) to the signalosome and
TBK1 will phosphorylate IRF3. Phosphorylated IRF3 proteins will homodimerize
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and traffic to the nucleus. Upon entering the nucleus, the IRF3 homodimer will
lay down on the Type I IFN promoter region and act as a transcription factor for
IFN a and IFN b. In order to maintain a prolonged activation of the RIG-I
pathway, IRF7 will also be upregulated in response to a positive feedback loop
after the expression of IFN-a and IFN-b has been initiated. IRF7 functions similar
to IRF3 by forming homo and heterodimers (with IRF3) once it is phosphorylated
by TBK1 to drive the Type I IFN expression [3, 30, 81, 82]. Figure 1.2 displays a
visual representation of the activation the RIG-I and MDA5 pathway and
subsequent induction of Type I IFNs.
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Figure 1.2: Detection of viral RNA by Pattern Recognition Receptors
(PRRs). RIG-I and MDA5 are involved in the recognition of viral RNA during
flavivirus infections. The RIG-I pathway is considered the predominant pathway
activated by flaviviral RNA. Activation of the RIG-I pathway leads to the induction
of Type I IFNs through the phosphorylation and subsequent activation of IRF-3
and 7. The production of Type I IFNs induces an antiviral state within virally
infected host cell. MDA5 is involved as a secondary measure to generate a
prolonged activation of the Type I IFN response [82].
The expressed IFN-a or IFN-b generated by the RIG-I and MDA5 pathway
will bind to Type I IFN receptors on the expressing cell as well as neighboring
cells. The Type I IFN receptor is a transmembrane Jak-Stat receptor with two
subunits, IFNAR1 and 2. The binding of the ligand to the Type I IFN receptor will
recruit JAK1 and Tyk2 to the receptor. The recruited JAK1 and Tyk2 will autoand trans-phosphorylate each other and the IFNAR subunits. The fully activated
receptor and phosphorylated JAK1 and Tyk2 will recruit STAT1 and STAT2
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proteins to the receptor. STAT1 is initially recruited and phosphorylated by JAK1,
and Tyk2 follows suit by recruiting and phosphorylating STAT2. Consequently,
the phosphorylated STAT proteins will heterodimerize and translocate to the
nucleus where they will form a transcription complex with IRF9. The transcription
complex, ISGF3, will bind to the IFN-stimulated response element (ISRE) to
initiate the transcription of vital Interferon Stimulated Gene (ISG). ISGs encode
for several hundred proteins involved in the innate antiviral immune response [3,
20, 80, 83]. Figure 1.3 depicts each step of the Type I IFN pathway leading to the
induction of ISGs.
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Figure 1.3: The Type I Interferon pathway. Once the Type I IFNs are
recognized by their respective Type I IFN receptor, the signaling pathway leads
to the phosphorylation of STAT1 and 2. The phosphorylation of STAT1 and 2
activates the signal transduction proteins leading to their heterodimerization.
STAT1 and 2 will form a complex with IRF9, designated ISGF3, that will generate
the induction of ISGs [84].
Due to the Type I IFN response’s capacity to induce an antiviral state in
both the target cell and neighboring cells, flaviviruses have evolved a number of
suppressive mechanisms to subvert the host cell’s immune response. The
flavivirus components involved in suppression of the Type I IFN response include
one or more non-structural proteins and the flavivirus 3’ untranslated region or
subgenomic flavivirus RNAs (sfRNA). Although the strategies for suppressing the
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Type I IFN response utilize shared components of flaviviruses, the suppressive
mechanism is drastically different between members of the genus [3].
As with other flaviviruses, the ZIKV sfRNA decreases degradation of
uncapped viral RNA and dysregulates host cell mRNA stability by stalling the
host cell ribonuclease, XRN1. The sfRNA has multiple hairpin structures that will
cause the XRN1 to stall and become ineffective at degrading both viral and host
cell RNA. The importance of the sfRNA’s XRN1 stalling activity has been
elucidated for WNV, DENV and other notable members of the Flaviviridae family
including Hepatitis C virus and bovine diarrheal virus [85]. Previous research
regarding sfRNAs has also indicated that the untranslated RNA is also
responsible for antagonizing the Type I IFN response directly in ZIKV, West Nile
virus (WNV), Dengue virus (DENV), and Japanese encephalitis virus (JEV)
infected cells. Unlike the shared stalling activity mechanism, the method by which
the sfRNA antagonizes the type I IRN response differs between each flavivirus.
DENV’s sfRNA binds to the RIG-I activing enzyme TRIM-25, effectively
suppressing the activation of RIG-I dependent IFN production [86]. WNV and
JEV’s sfRNA targets the RIG-I pathway downstream relative to DENV’s sfRNA
by antagonizing IRF-3 and 7 [87, 88]. In contrast, ZIKV follows suit with DENV by
antagonizing RIG-I and MDA-5’s induction of IFNs. However, the mechanism by
which ZIKV suppresses both of these activation pathways is still unclear at this
time [89].
Along with the sfRNA mediated antagonism, NS1,NS2A, NS4B, NS5 and
the NS2B-NS3 complex have all been shown to be involved in the suppression of
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the Type I IFN response for one or more flaviviruses. To date, previous research
has elucidated the importance of the NS1, NS2B-3, NS3, NS4B, and NS5
proteins involvement in ZIKV’s antagonism of the type I IFN response at multiple
junctions within the pathway [2, 3, 90]. During a ZIKV infection, NS1, NS2A and
NS4B all target TBK1 to inhibit the synthesis of the downstream IFNs [20, 90].
Interestingly, Xia et al. demonstrate that a single mutation in the amino acid
sequence of the NS1 protein (A188 to V) generates a significant difference in the
proteins capacity to suppress the IFN response both in vitro and in vivo through
TBK1 antagonism. After comparing pre-epidemic (prior to 2012) and postepidemic ZIKV isolates, the authors propose that the single amino acid mutation
may be a contributing factor for the increased capacity of post-2012 ZIKV strains
to cause major outbreaks [90]. However, more research will need to be
conducted in order to fully understand how the single mutation affected ZIKV’s
proclivity for generating epidemics. In comparison, NS4B and NS2A are also
utilized by DENV, YFV and WNV, but the antagonizing proteins inhibit STAT1
phosphorylation during all three viral infections. YFV also utilizes NS4B to
interact with STING to block the stimulatory effects of the protein on RIG-I [3].
NS2B-3 is the complex formed between the NS2B and NS3 proteins.
During a flavivirus infection, the two proteins will form a stable complex that
functions as a serine protease that will cleave both viral and host proteins. The
effects of the NS2B-3 complex on the host cell response during a ZIKV infection
are two-fold. During a ZIKV infection, the NS2B-3 complex will directly interact
with JAK1 to promote degradation and block the induction of RLR-mediated
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apoptotic pathways. By promoting the degradation of JAK1, NS2B-3 not only
depletes the levels of the protein, but will consequently inhibit JAK1 and STAT1
phosphorylation. The resulting suppression demonstrated by Wu et al. indicates
that the markedly lower levels of phosphorylated JAK1 and STAT1 proteins
significantly decreased the expression of multiple ISGs. NS2B-3’s secondary
effect on the host cell response blocks the RLR- triggered apoptotic pathway by
inhibiting the cleavage of caspase 3 and Poly ADP ribose polymerase (PARP).
Wu et al. confirmed the effects of ZIKV on the RLR-triggered apoptotic pathway
by exposing ZIKV infected HT180 cells to poly (I:C). Cell cultures at 24 and 48
hours post infection showed lower poly (I:C) induced cell death compared to noninfected cultures. The research group also confirmed that ZIKV infected cultures
with higher amounts of NS2B-3 were more resistant to poly (I:C) induced
cleavage of caspase 3 and PARP. However, the exact mechanism by which
NS2B-3 is blocking the cleavage of capase 3 and PARP is still currently unclear.
These findings suggest that NS2B-3 is a vital component for generating
productive ZIKV infections through the reduction of ISG expression and
protection of infected cells from RLR-triggered apoptosis [20].
Between all of the flaviviral NS proteins involved in subverting the host cell
immune response, NS5 is the most commonly utilized. During an flaviviral
infection, NS5 functions as a methyltransferase and a RNA dependent RNA
polymerase. NS5’s involvement in inhibiting the host cell response has been
demonstrated for ZIKV, DENV, YFV, WNV, JEV, Tick-borne encephalitis virus
(TBEV), Langat virus (LGTV), Spondweni virus (SPOV) [2, 3, 15, 80, 91]. As with
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the other NS proteins, the NS5 mechanism of antagonism is varied between the
flaviviruses that employ it for immune suppression. WNV, TBEV, and LGTV’s
NS5 targets the IFNAR1 receptor by dysregulating IFNAR1 maturation and
reducing the receptors cell surface expression. The target of JEV’s NS5 protein
is thought to be inhibition of JAK activation, but the mechanism for generating the
inhibition is currently unclear. YFV, DENV and ZIKV’s NS5 protein shares a
commonality in their target, STAT2, but the mechanism and host proteins
involved in the antagonism diverge. DENV and YFV NS5 proteins both require
host cell proteins, UBR4 and TRIM23 respectively, to carry their antagonistic
effects [2]. However, the mechanism of action between DENV and YFV’s NS5
protein differs in that DENV’s NS5 causes the proteosomal degradation of
STAT2, while YFV’s NS5 suppresses the pathway downstream relative to DENV
by inhibiting ISG translation [2, 3]. Similar to the DENV, the ZIKV NS5 protein will
interact and lead to the proteosomal degradation of the human/primate STAT2
protein. Interestingly, SPOV, a flavivirus belonging to the same serocomplex as
ZIKV, does not have the same mechanism of antagonism or target regarding its
NS5 protein. SPOV’s NS5 protein suppresses the induction of ISGs similar to
YFV, but the target for generating this effect is still currently unknown [2]. Unlike
DENV, ZIKV’s NS5 does not require the cooperation of the host protein UBR4,
an E3 ubiquitin ligase, to effectively antagonize STAT2. During DENV’s NS5
antagonism of STAT2, the NS5 protein acts as a bridge between UBR4 and
STAT2. The interaction mediated by the DENV NS5 protein allows UBR4 to
promote the degradation of STAT2 by host proteasomes. ZIKV’s NS5 follows suit
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by promoting the degradation of STAT2 by host proteasomes like DENV, but
identity of the cooperative host cell ubiquitin ligase involved in the process, or if
ZIKV’s NS5 protein even requires a host cell protein to generate the antagonistic
effects is still unclear at this time [2, 92, 93].
The degradation of the STAT2 protein by ZIKV’s NS5, and the cooperative
effects of the sfRNA and other NS proteins results in the effective inhibition of the
Type I IFN response in primates. The inhibition of the Type I IFN response is
required for ZIVK to generate a productive infection prior to the recognition and
subsequent clearing of the infection by the adaptive immune response.
Therefore, understanding and elucidating the mechanisms by which ZIKV
generates the antagonism of the Type I IFN in humans, non-human primates and
a diversity of other species is an important avenue of research for aiding in the
development a more effective animal model and may lead to the discovery of
effective therapeutic treatments against ZIKV and other flaviviruses.
Current Zika Virus Animal Models
A major component of vaccine and therapeutic treatment development is
the availability of an animal model that has the capacity to recapitulate human
disease in order to test the efficacy and safety of novel treatment options. Along
with the capacity to recapitulate human disease an ideal animal model would be
widely available, easy to handle, produce large litter sizes, have comparable
anatomy and physiology to humans, and require minimal effort in housing and
care. Rodents, especially the common house (Mus musculus) and Sprague-
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Dawley rats (Rattus norgevicus), are commonly used in viral and biomedical
research due to their natural characteristics meeting the optimum criteria.
Current ZIKV research has relied heavily upon type I IFN immunodeficient
mice (Mus muscus) because of their ability to recapitulate the severe
neurological manifestations observed in human infections [3, 20, 21, 27, 41, 9395]. Studies have relied on using Type I IFN immunodeficient mice as the
primary ZIKV disease model due to key differences in the interaction between the
human and mouse STAT2 protein with the ZIKV NS5 protein. The mouse STAT2
protein, unlike human STAT2, is not antagonized by the ZIKV NS5 protein. An
immunocompetent mouse with the unblocked STAT2 protein is able to mount a
functional innate antiviral response to ZIKV infection [3, 83, 93]. Without
effectively knocking out the ability of the mouse’s capacity to produce the Type I
IFN response, the currently accepted ZIKV animal model would be ineffective at
recapitulating a human ZIKV infection.
Type I IFN immunodeficient mice are produced by single, double and triple
knockouts in key proteins of the Type I IFN pathway. The genetic modification
effectively depletes the animal’s ability to mount a functional Type I IFN immune
response against ZIKV infection. The resulting animal model will present with
viremia, high viral loads in multiple organs, severe neurological symptoms, and in
some cases death [21, 27]. The wide availability, low maintenance cost and
relatively effective recapitulation of human ZIKV infections of the immunodeficient
mice is beneficial, but the use of an immunodeficient animal model in pathogen
related research is highly scrutinized due to the questionable validity of research
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findings obtained from an animal with a disrupted immune response. As well, the
outcome of death in many cases during ZIKV infection in the immunodeficient is
arguably ineffective at recapitulating the human response since it is extremely
rare for death to be the consequence. A considerable amount of virologist
contest immunodeficient animal models arguing that conclusions drawn from the
data are not applicable in real world scenarios. The concern regarding
applicability stems from the fact that the research will be applying conclusions
derived from the incomplete immune response of the genetically altered mice to
the competent immune response of a human during a ZIKV infection.
It is important to note that three immunocompetent animal models have
been utilized in previous research, the rhesus macaque (Macaca mullatta),
Syrian golden hamsters, and guinea pigs (Cavia porcellus) [54, 96-98].The
rhesus macaque model has precedence as a nonhuman primate ZIKV model
that effectively recapitulates human symptoms, but the extreme lack of
availability and substantial cost for a single animal makes their use in research
highly impractical. Guinea pigs and Syrian golden hamsters, on the other hand
are the most suitable candidates for a ZIKV animal model. However, the status of
both animals as the accepted ZIKV model remains in the preliminary phase of
development.
Novel Animal Models and
Primary Cell Lines
As noted above, very little research assessing the effects of ZIKV across a
diversity of species has been conducted. Therefore, this study looks to expand
upon the current breadth of knowledge regarding ZIKV in mammalian species by
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examining the susceptibility and immune regulation of primary cell lines derived
from three unique animal models. The deer mouse, Jamaican fruit bat, and
Syrian golden hamster have been selected as the animal models for this study
because of their ease of handling, minimal requirements for housing and
availability at the University of Northern Colorado. From the selected mammals,
three significant tissue types have been selected for assessment with ZIKV
experimental infections. The primary cell lines established and evaluated during
this study include mixed primary kidney and lung cell cultures, and primary
hepatocyte cultures. The tissue types and animal models were selected for their
employment in previous studies involving the permissibility and host cell
response during ZIKV infection.
Due to the established presence of ZIKV in the urine of humans and other
susceptible species, multiple research groups have evaluated the tropism of
ZIKV for kidney cells [59, 99, 100]. A recent study by Alcendor, J., demonstrates
the permissiveness of human glomerular podocyte, renal glomerular endothelial
cells, and mesangial cell cultures to ZIKV infection. ZIKV susceptibility of these
cell types was confirmed in samples from all three cell types via
immunofluorescent staining, Polymerase Chain Reaction (PCR) and Reverse
Transcriptase-quantitative Polymerase Chain Reaction (RT-qPCR) [59].
Diteepeng et al.’s findings also support for the kidney involvement during ZIKV
infection by demonstrating the permissiveness of the Rhesus Macaque kidney
cell line, LLC-MK2, to the virus. The study found that on average, 40% of the
LLC-MK2 cells within a culture were infected with the SV0010/15 isolate
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(Thailand, 2015; Asian lineage) by marking and sorting infected cells with a BD
FACS cytometer and a mouse monoclonal pan flavivirus antibody [100].
The susceptibility of liver and lung cells to ZIKV infection have also been
evaluated in previous research, albeit to a lesser extent, in human and nonhuman cell lines. Using a shotgun approach, Chan et al. evaluated the
susceptibility of 33 different immortalized cell lines derived from both human (18)
and non-human (15) species. ZIKV susceptible cell lines were determined by
immunofluorescent staining with a mouse antibody against the ZIKV NS1 protein
and detection of viral RNA through probe based RT-qPCR. The results of both
detection assays indicated susceptibility of human derived lung cultures, Calcu-3
and HFL, and human derived hepatocyte cultures, Huh-7, to both PRVABC59
and 976 Ugandan (Ugandan, 1976; African lineage) isolates [40]. The
aforementioned study by Diteepeng et al. also evaluated the susceptibility of 11
different human derived cell lines to the SV0010/15 and MR766 ZIKV isolates.
The results of their investigation support the findings of Chan et al. by
demonstrating the susceptibility of human derived lung cultures, A549, and
human derived liver cultures, HEP3B and HepG2, to both ZIKV isolates [101].
These in vitro findings involving ZIKV, along with the well-established
involvement of the lung tropism, during Dengue virus (DENV) infections, and the
liver tropism, during yellow fever virus (YFV) and DENV infections, affords the
basis by which the selected tissue types for establishing primary cell culture were
chosen [102, 103].
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The Syrian Golden hamster was selected as an attractive disease model
for ZIKV due to their well-documented capacity to recapitulate human disease for
a number of viral infections, including flaviviruses. Most relevant to the proposed
research project, Syrian Golden hamsters have been utilized in a considerable
number of research studies involving members of the Flavivirus genus. The
rodent model has been employed in studies involving ZIKV, YFV, DENV, Modoc
virus (MODV), and West Nile Virus (WNV) [104-107]. Two recent studies
involving Syrian golden hamsters have generated contradictory findings
regarding the susceptibility of the animal model to ZIKV infection. Ragan et al.
evaluated 17 different North American species representing birds, rodents,
amphibians, reptiles, and livestock to ZIKV infection. The study evaluated each
animals permissiveness to the PRVACB59 and FSS13025 (2010 Cambodian
isolate; Asian lineage) ZIKV isolates and replication by testing for viral RNA with
RT-qPCR and tittering infectious virus levels with Plaque forming unit (PFU)
assay in sera and kidney, liver, and spleen tissues. Seroconversion of the
selected animals was also evaluated through plaque reduction neutralization
tests. The results of the study indicated that all 6 of the Syrian golden hamsters
employed in the study were not susceptible to ZIKV infection. The researchers
were unable to detect infectious virus, viral RNA, or antibodies in any of the
collected Syrian golden hamsters [108]. However, Miller et al.’s discoveries in a
study evaluating the potential of Syrian golden hamsters and Strain 13 Guinea
pigs as potential ZIKV animal models contradict Ragan et al.’s findings. The
study evaluated the permissiveness of both animal models to the ArD41525
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(Senegal 1984 isolate; African lineage) and CPC-740 (Phillipines 2012; Asian
lineage) ZIKV isolates through subcutaneous (SQ) and intraperitoneal (IP)
inoculations. Susceptibility to ZIKV infection was evaluated by daily signs of
disease monitoring, histopathological analysis on collected organs, viral tittering
in sera by PFU assays, and ZIKV reactive antibody levels with plaque reduction
neutralization test assays. High levels of neutralizing antibodies were detected in
animals challenged with both ZIKV isolates regardless of inoculation route.
However, viremia was only detected in the sera samples of hamsters inoculated
IP with the ArD41525 isolate. The results of Miller et al.’s work provides
supporting evidence for the potential of Syrian golden hamsters as an
immunocompetent ZIKV disease model, as well as providing more evidence
regarding the significant differences between the virulence of ZIKV’s African and
Asian lineages [96].
Between the three selected animal models, Jamaican fruit bats are the
most unique animal model involved in the current study. The initial interest in
evaluating bats as a novel ZIKV model originated from a research study from
1955 involving experimental ZIKV infections of the little brown bat (Myotus
lucifugus). Reagan et al. carried out 5 different routes of inoculation
(intraperitoneal, intrarectal, intradermal, intracerebral, and intranasal) to
extensively test the susceptibility of the small cave bat to ZIKV infection. The
results indicated that small cave bats are susceptible to the multi-passaged
MR766 ZIKV isolate via all inoculation routes excluding intranasal. The
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researchers also observed severe neurological manifestations in the bats on
days 4-7 post infection [109].
Bats are attractive as potential animal in viral research because of the
well-established role of bats as the reservoir host for a wide variety of families
and genera of viruses [110, 111]. A reservoir host is distinguished from a host
that experiences disease by the animal’s capacity to become persistently
infected and transmit the microbe with little to no clinical disease manifestations.
Within the flavivirus genus alone, 21 different members have been isolated from
one or more species of bats [110, 112-115]. Relevant human pathogens of the
21 flavivirus species include St. Louis encephalitis virus (SLEV), WNV, DENV,
JEV, YFV, and ZIKV. As well, serological evidence from multiple survey studies
has also demonstrated the presence of DENV, SLEV, WNV, and YFV reactive
antibodies in sera from Jamaican fruit bats [114, 116]. A recent study from
Malmlov et al. supported the findings of ZIKV susceptibility from the serological
surveys in wild bats by conducting an in vivo challenge of captive Jamaican fruit
bats to the PRVABC59 ZIKV isolate. Although the inoculated bats did not present
with any clinical manifestations during the study, viral RNA was detected through
probe-based RT-qPCR in the brain tissue of one bat at day 2 post inoculation
and the urine of two bats at days 3 and 5 post inoculation. Moderate levels of
ZIKV reactive antibodies relative to the human convalescent control (Bat:
3,200|Human: >12,800) were also detected in the serum of all of the bats at their
selected euthanasia time points during the 28-day research timeline.
Histopathological analysis of lung, heart, testes, brain, and salivary tissue from
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the infected bats indicated that lesions likely induced by ZIKV infection were
present in the testes, brain, and salivary glands of the bats [117]. Reagan et al.’s
and Malmlov et al.’s findings alone provide a solid reasoning for investigating
ZIKV susceptibility in bats, but the evidence from countless studies regarding the
association between bats and multiple flaviviruses reinforces the support for the
Jamaican fruit bat’s potential as a viable immunocompetent ZIKV animal model.
In contrast to Syrian golden hamsters and Jamaican fruit bats, deer mice
only have minimal use in previous research related to members of the Flavivirus
genus. Only one study involving deer mice and ZIKV has been published to date.
The aforementioned Ragan et al. study evaluated the potential of 17 North
American species to serve as ZIKV hosts. This included an investigation into the
susceptibility of deer mice to ZIKV. Ragan et al. found that none of the evaluated
deer mice (n=5) were susceptible to ZIKV infection when assessed using virus
isolation and PCR [108]. Although these findings are somewhat disconcerting to
the goals of the current study, confirming or providing evidence against the
findings of the previous study adds to the weight to the findings yielded in the
current study. Aside from Ragan et al.’s work, deer mouse involvement in
previous viral research has primarily examined the rodent’s role as a reservoir
host for MODV and Sin Nombre (Orthohantavirus) [118-120]. Understanding how
a reservoir host can become infected without the manifestation of disease
provides an interesting research avenue aimed at aiding in the development of
therapeutic treatments for controlling the same infection in humans. The current
study has selected deer mice as a member of the evaluated species in the hopes
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that our findings will allow for the comparison of ZIKV’s virulence and host cell
immune response between a pathogenic model and a reservoir host (nonpathogenic) model.
Specific Aims
The lack of an adequate immunocompetent animal model for ZIKV
research poses a considerable concern for current research regarding the virus
and for the design and testing of efficacious vaccines to protect against future
ZIKV outbreaks. Along with supplementing the current understanding of ZIKV’s
effects across species, the current study looks to provide the pilot data for the
potential development of an immunocompetent ZIKV vaccine model. As well,
expression levels of genes associated with the Type I IFN response will be
compared between control and ZIKV treated cell lines to elucidate novel
information regarding the interaction and suppression of ZIKV with one of the
primary innate anti-viral immune response pathways. In doing so, we hope to
provide information that will aid in the development of therapeutic treatments
against ZIKV to mediate the burden of the viral outbreaks until a FDA-approved
vaccine is commercially available.

A1

Determine the susceptibility of primary kidney cell, pulmonary cell
(lung), and hepatocyte (liver) to ZIKV by evaluating cell pellet
samples with endpoint PCR for ZIKV RNA to determine
susceptibility.

H1

We hypothesize that primary cell cultures derived from the
Jamaican fruit bat and Syrian golden hamster will have detectable
levels of ZIKV RNA in all of the 72 hour post infection timepoint
samples. Deer mouse cell culture samples will not have detectable
levels of ZIKV RNA at the 72 hour timepoint.
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A2

Determine the permissiveness of established primary cell lines to
ZIKV replication by evaluating cell culture suspension samples with
endpoint PCR for ZIKV RNA to determine permissiveness to ZIKV
replication. The titer of infectious virus in ZIKV treated cell culture
suspension will also be determined using the Reed Muench viral
titer assay method.

H2

We hypothesize that primary cell lines from the Jamaican fruit bat
and Syrian golden hamster will have detectable levels of ZIKV RNA
in all of the 72 hour timepoint samples and viral titer will be present
in liver and lung derived cell cultures from both animals. Deer
mouse cell culture samples will not have detectable levels of ZIKV
RNA or infectious virus in 72 hour viral treated suspension
samples.

A3

Genes associated with the Type I IFN response will be examined in
each cell line. Transcript levels of STAT1, JAK1, ISG15 and Oas1b
will be determined via semi-quantitative PCR to give insight into the
expression and possible viral suppression of the selected genes in
response to ZIKV infection.

H3

We hypothesize that JAK1 and STAT1 expression will significantly
increase in samples with ZIKV RNA and infectious virus present in
cell culture suspension. ISG15 and Oas1b will have little to no
increases in gene transcript expression in samples with ZIKV RNA
and infectious virus present in cell culture suspension.
Chapter Summary

Zika virus has become a major concern regarding public health due to its
exceptional rate of spread, novel modes of transmission, association with severe
neurological symptoms and lack of an available vaccine or therapeutic treatment.
Although ZIKV was first isolated over 70 years ago, the lack of major outbreaks
until 2007 has led to a significant deficiency in the understanding of ZIKV’s
characteristics and pathology in humans as well as across a diversity of species
[24]. It is likely that ZIKV will continue to spread and become endemic in regions
previously protected from transmission due to the increasing ranges of ZIKV’s
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primary vector, Aedes species mosquitoes [45, 46]. Therefore, it is imperative
that current research works towards resolving the lack of information regarding
ZIKV and developing a safe and efficacious vaccine against the virus. The lack of
an adequate immunocompetent animal model for ZIKV research poses a
considerable concern for current research regarding the virus and for the design
and testing of efficacious vaccines to protect against future ZIKV outbreaks.
Along with supplementing the current understanding of ZIKV’s virus hostinteraction across species, the current study looks to provide the pilot data for the
potential development of an immunocompetent ZIKV vaccine model. As well,
components of the Type I IFN response, will be investigated in susceptible cell
lines to elucidate novel information regarding the interaction and suppression of
ZIKV with one of the primary innate anti-viral immune response pathways. In
doing so, we hope to provide information that will aid in the development of
therapeutic treatments against ZIKV to alleviate the burden of the virus until a
FDA- approved vaccine is commercially available.
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CHAPTER II
METHODOLOGY
Purpose of the Study
The purpose of the current study aims to provide data and insight into two
critical areas of Zika virus (ZIKV) research. As a primary objective, the current
study looks to provide the pilot data required to warrant further research into the
three selected mammalian species as novel immunocompetent ZIKV animal
models. Establishing a novel immunocompetent animal model would aid future
research involving development and testing of vaccines and therapeutic
treatments against ZIKV. Along with providing pilot data, we seek to provide
insight into virus-host interaction of ZIKV with three mammalian species as a
secondary objective. Here, we investigate ZIKV susceptibility and host cell’s
antiviral response in primary cell lines derived from three mammalian species.
Results from this study will benefit the understanding of ZIKV’s virus-host
interaction across species. The current study utilizes primary cell culture from
three novel animal models, Ribonucleic acid (RNA) extraction, complementary
Deoxyribonucleic acid (cDNA) synthesis, standard-endpoint Polymerase Chain
Reaction (PCR), and semi-quantitative PCR techniques to investigate the
proposed aims and hypotheses.
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Establishing Primary Cell Lines
In order to establish the primary cell lines necessary for the present
research, three different tissues, liver, lung and kidney, were collected from deer
mice (Peromyscus maniculatus), Syrian golden hamsters (Mesocricetus auratus)
and Jamaican fruit bats (Artibeus jamaicensis) for the establishment the primary
cell cultures through accepted standard operating procedures (SOP). Deer mice
and hamster tissues were collected from males of 6-9 weeks of age at the time of
necropsy. Due to the lack of a standardized method for determining the age of
bats, the only selection parameter for the Jamaican fruit bats was ensuring that
the subjects were males. Three sets of each primary cell culture were derived
from three different male bats and deer mice (18 total primary cell cultures) to
represent biological replicates. Due to initial issues with establishing all of the cell
types from a single animal, the primary cell cultures utilized in the experimental
infection are not all drawn from the same animal. Continuous problems with
establishing viable primary kidney and liver cultures from the Syrian golden
hamsters resulted in only establishing three sets of primary lung cell cultures
from the third animal model. Although the lack of primary cell types from all three
tissues in Syrian golden hamsters significantly limits the ability to compare
between all three animal models, it is still relevant to evaluate the established
cultures in regard to the goal of the current study. In summation, 3 sets of 7
different primary cell lines (21 total primary cell cultures) were established the
current study. For all cell types, cells were passage using a standard 1:10 split
with trypsin. Hepatocytes were centrifuged at 50 x g while all other cells were
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spun at 300 x g. Table 1 provides a visual representation of the established
cultures.
Animals were humanely euthanized per the deer mouse IACUC protocol
(1109B-AH-DM-14, Hamster Animal Research Facility IACUC holding protocol,
Bat Animal Research Facility IAUCAC colony protocol) and no work was done on
live animals. Prior to use in the current study, animals were cared for and housed
by the University of Northern Colorado’s Animal Research Facility Staff as
outlined in the IACUC protocols. In brief, the humane euthanasia of the animals
was carried out through respiratory administration of isoflurane (3% to effect)
followed by cervical dislocation and thoracotomy to ensure death prior to tissue
collection. Please see the appendix for more information regarding the IACUC
protocols. Kidney and lung tissue were collected in 100 mm TC dishes with
appropriate collection media, and the liver tissue was perfused with perfusion
buffers using a modified two step collagenase perfusion method (outlined below)
prior to collection. All of the primary cell lines were initially seeded in a T-25 or T75 tissue culture flask depending on the resulting cell yield. Initial cultures were
passaged at least once after reaching 90-95% confluency prior to use in the
experimental infections.
Primary Pulmonary Cell Culture
Primary Pulmonary cell (PC) cultures were established following a
modified Sobczak, et al. Pulmonary Microvascular Endothelial cell isolation with a
collagenase and elastase enzymatic digestion protocol [121]. Prior to conducting
each necropsy, a T-75 flask was coated with a 2% porcine gelatin solution and
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allowed to dry for at least two hours prior to use. If the flasks were coated the day
before, they were allowed to dry for two hours and then they were stored at 4 oC
overnight. The coated flask stored in the refrigerator were warmed to room
temperature prior to being utilized for cell culture. During each necropsy, excised
lung tissue was collected in 15 ml of ice-cold Dulbecco’s Modified Eagle Medium
(DMEM) initially and then transferred into a 100 mm TC dish. The lung tissue
was minced into fine pieces using sterile scissors and then collected in 15ml
conical containing 15ml of a collagenase and elastase enzyme mixture
suspended in DMEM. The lung tissue was allowed to digest in the enzyme
cocktail for 45 minutes on a rotator at 37oC. Once the enzymatic digestion was
complete, the digested tissue suspension was aspirated into a 30 ml syringe
through a 20-gauge needle. The suspension was expressed from the 30 ml
syringe and collected back into the 15 ml conical. The previous step was
performed at least twelve times on each suspension to break up any clumps to
ensure a single cell suspension. The subsequent single cell suspension was
pipetted into a 10 ml pipette and the leftover tissue chunks were allowed to settle
prior to slowly dispensing the resulting supernatant back into the 15 ml conical
tube. The purpose of the previous step was to remove any leftover chunks that
were too large to be digested by the enzyme cocktail. In order to disrupt any
remaining enzyme activity, the single cell suspension was mixed with 15 ml of
isolation media (20% FBS DMEM w/ 1x Penicillin/Streptromycin) and collected in
a sterile 50 ml conical tube. Cells in the suspension were pelleted down by
centrifugation at 400 x g for five minutes and the resulting supernatant was
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decanted. The cells were suspended and washed in 3 ml of 0.1% Bovine Serum
Albumin/Phosphate-buffered saline solution, and centrifuged at 400 x g.
Supernatant was decanted again and the cell pellet was re-suspended in 11 ml
of the Vasculife with the EnGS-Mv life factors kit supplemented with 1x
pen/strep/fungizone. The 11 ml of PC cell suspension was seeded into a precoated T-75 flask and placed in an incubator set at 37oC with 5% CO2. A cell
count was not performed on the cell suspension product, because all of the
extract PC cells were pooled and used to seed single T-75.
New PC cultures were allowed to incubator for one full day before media
was exchanged. All of the media was changed on the first day post inoculation
and then half of the media was exchanged every 2-3 days. Once the PC cultures
reached 90-95% confluency, they were regularly split at a 1:10 ratio. During the
third or fourth passage, PC cell suspensions were used to seed two T-75 flasks.
The first culture was used for the experimental infections and the second culture
was passaged and frozen back in liquid nitrogen for future use. PC cells would
be frozen back in four 1.5 ml cryovials suspended in freeze medium (10%
dimethylsulfoxide/ 20% FBS DMEM). The PC cultures prepared for the
experimental infections were allowed to grow to 90-95% before being split at a
1:20 ratio into 10 T-12.5 flasks. The final volume of the T-12.5 flasks were
brought up to 3 ml with Vasculife media and the cultures were allowed to grow
until they reached 85-90% confluency before they were utilized in experimental
infections.
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Primary Kidney Cell Cultures
Primary kidney cell were established using a protocol previously
developed by the Hawkinson laboratory. Excised kidneys were collected under a
BSL2 Biosafety cabinet in a 100 mm tissue culture dish with 10 ml of 1x
Dulbecco’s phosphate buffered-saline (DPBS) and minced into small pieces
using a #11 scalpel. The 1x DPBS and kidney chunk solution was transferred
into a 50 ml conical to allow for the kidney pieces to settle at the bottom. The
DPBS was aspirated from the 50 ml conical tube and the kidney pieces were
transferred into a 50 ml sterile pleated flask containing a stir bar and 12 ml of
0.25% trypsin. The kidney pieces were enzymatically and mechanically digested
for 15 with the trypsin and rotating stir bar on a stir plate. The pleated flask with
the trypsin and kidney piece suspension was placed on a stir plate and allowed
to mechanically and enzymatically digest for 15 minutes at 25 oC. After
completing the digestion step, the resulting suspension was transferred back into
the original 50 ml conical tube. The undigested kidney cell chunks were allowed
to settle to the bottom before being transferred to a new 50 ml conical tube
containing 20 ml of 10% FBS DMEM. The addition of the 10% FBS DMEM to the
cell suspension was important to inhibit any remaining trypsin activity. After
neutralizing the trypsin, the kidney cells were pelleted down by centrifugation at
400 x g for 5 minutes. The resulting supernatant was decanted and the cell pellet
was re-suspended in 10 ml of 10% DMEM before being centrifuged again at 400
x g for 5 minutes. The previous step was repeated again with another 10 ml of
10% DMEM for a total of three wash steps. After completing the third wash step,
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the resulting pellet was re-suspended in 10 ml of 10% FBS DMEM and seeded
into a T-25 flask. Initially, kidney cell suspensions were counted and seeded at
the recommended 0.7x106 cells/ml seed density, but the yielded kidney cell
suspensions were eventually pooled into a single T-25 after losing multiple
kidney cell cultures due to low seeding densities. The volume of the T-25 was
brought up to 5 ml with 10% FBS Dulbecco’s Modified Eagle Medium with 1x
pen/strep/fungizone and incubated at 37oC with 5% CO2. After 24 hours, all of
the media was exchanged with fresh 10% FBS DMEM. Half of the media was
exchanged every 2-3 days until the cultures were ready to be split into the T-25
flasks for experimental infections.
Primary Hepatocyte Cultures
Hepatocytes were isolated using a modified two-step collagenase
perfusion method as outlined in Li, et al. for the isolation of adult mouse
hepatocytes [122]. Ca+2 and Collagenase Type I (Worthington Biochemical)
concentrations (5 mM, and 200 U/mL, respectively) of perfusion buffer II, FBS
and dexamethazone concentrations (20% and 1 µM, respectively) in the
hepatocyte attachment media, and centrifugation speeds (50-100 x g) were
altered from the selected protocol in order to optimize hepatocyte cell yield and
viability [123-128]. Prior to conducting each necropsy, two T-75 flasks were
coated with 4 ml of a 0.1 mg/ml Poly-D-lysine solution (mol wt 70,000-150,000)
and allowed to dry for at least two hours prior to use. If the flasks were coated the
day before, they were allowed to dry for two hours and then they were stored at 4
o

C overnight. Coated flask stored in the refrigerator were allowed to warm to

49

room temperature prior to being utilized for cell culture. In order to perform the
perfusion, a peristaltic pump fitted with 6.3 mm medical tubing was used to
perfuse the two buffers through the liver. A 36 ½ gauge needle was attached to
one end of the pump’s tubing and the other end of the tubing was placed in the
corresponding buffer at each procedural step. Both of the required perfusion
buffers were made up to 24 hours prior to hepatocyte isolation and warmed up in
a water bath to 43 oC for at least 30 minutes before the procedure. The 43 oC
temperature setting was employed to achieve the optimal temperature output of
the perfusion buffers after flowing through the peristaltic pump tubing. It is
important to note that the collagenase can only be added to perfusion buffer II
(Hanks Balanced Salt Solution with Ca+2 /Mg+2 and 25 mM HEPES, 0.72%
Bovine Serum Albumin and increased Ca2+ concentration of 3 mM) 30 minutes
prior to conducting the procedure. The enzymatic activity of collagenase will
begin to decrease after 30 minutes at 37 oC. Once the liver was exposed, the left
and right lobes of the liver were gently lifted with sterile forceps and the intestines
are pushed to the right side of the animal to expose the hepatic portal vein and
inferior vena cava. A 36 ½ gauge needle was inserted into the hepatic portal vein
and the peristaltic pump was turned on with a flow rate of 5 ml per minute. The
inferior vena was severed to allow for the perfusion buffers to effuse after
circulating through the liver. The liver was initially perfused with perfusion buffer I
(Hank’s Balanced salt solution w/out Ca+2 and Mg+2 and 0.5 mM EDTA) for ten
minutes. After 2 to 3 minutes, the flow rate was increased from the 5 ml per
minute to 10 ml per minute and left at this rate for the remainder of the
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procedure. Observing a color change of the liver from red to a light yellow and an
marked ballooning effect of the left and right lateral lobes during the initial
perfusion indicates a successful start to the perfusion. The first step of the
perfusion method with perfusion buffer I was used to washout and remove any
blood and calcium present in the liver. The purpose of removing the calcium from
the tissue is to disrupt any calcium dependent adhesion factors that are
maintaining intercellular connections in the liver [129, 130]. After completing the
first perfusion, the tubing was transferred to the perfusion buffer II w/ collagenase
reservoir and the buffer perfused the liver for an additional 10 minutes at a
flowrate of 10 mls per minute. Perfusing the liver with the collagenase buffer
enzymatically cleaves any remaining intercellular connections between
hepatocytes as well as other non-parenchymal cells. Upon completion of second
perfusion, the liver was carefully excised from the animal and collected in a 100
mm TC dish with 20 ml of perfusion buffer II w/ collagenase. To release the
hepatocytes from the digested liver, the Glisson’s capsule was gently pulled
apart using sterile forceps and then the liver was shaken using one of the forceps
to dissociate the hepatocytes into the suspension. Figure 2.1 shows an image of
the isolated hepatic portal vein and vena cava, color changes resulting from
successful perfusion, and resulting liver cell suspension after excision and
removal of the Glisson’s capsule. The resulting suspension was filtered through a
100 µM pore cell strainer into 50 ml conical tube to remove any connective tissue
or undigested tissue fragments. During the bat hepatocyte procedures, the
suspensions had to be spilt into two 50 ml conical tubes due to the higher density
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of cells in resulting from a relatively larger organ. The collagenase enzymatic
activity was disrupted by adding 20 ml of hepatocyte wash media (7% Williams E
medium with 1x Penicillin/Streptromycin/Insulin-Transferrin-Selenium/Sodium
pyruvate) to the 50 ml conical tubes. The filtered suspension was centrifuged at
50 x g for 3 minutes at 22 oC. It is very important to keep the centrifugation speed
of hepatocytes below 100 x g. Previous research has shown that going above
100 x g when centrifuging hepatocytes can significantly damage the cells and will
result in a substantial loss of hepatocyte yield and viability [123, 124, 131]. The
supernatant from the centrifuged tube was aspirated with a 25 ml serological
pipette and the previous wash step was repeated twice with 20 ml of hepatocyte
wash media (three washes total). The resulting cell pellet was brought up in 10
ml of hepatocyte attachment media (20% FBS William’s Complete media with 1x
penicillin/streptomycin/fungizone/1x Insulin-Transferrin-Selenium). Hepatocytes
yielded from the procedure were split evenly (5 ml in each) between two T-75
Poly-D-lysine coated culture flask. The total volume of the T-75 was brought up
to 11 ml with hepatocyte attachment media and the flaks were placed in the
incubator for 24 hours. In the deer mice hepatocyte cultures, the attachment
media is switched to a 1:1 mixture of 5% FBS F-12K (w/ ½ x
Penicillin/Streptromycin/Amphotericin) and Vasculife EnGS-Mv life factor media
after 24 hours. Conversely, Jamaican fruit bat hepatocytes were switched to a
formulation of 10% FBS F-12K only after the 24 hours attachment period. Half of
the media exchanged every 2-3 days until the cultures were ready to be split into
the T-12.5 flasks for experimental infections.
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Figure 2.1: Step by step images of the two-step perfusion method for the
isolation of primary hepatocytes. Image (A) The isolated hepatic portal vein
and inferior vena cava. (B) The insertion of the perfusion needle into the hepatic
portal vein. (C) The initial color change/blanching caused by successfully
perfusion of buffer I the liver. (D) The complete color change/blanching and
ballooning of the liver caused by both perfusion buffers. (E) The excised liver
after perfusion in a 100 mm TC dish. (F) The single cell suspension generated by
the removal of the Glisson capsule [132].
Stock Virus
In preparation for the experimental infections, stock PRVABC59 ZIKV P4
(Passage 4) was obtained from Dr. Tony Schountz’s lab at Colorado State
University. This stock came from the Centers for Disease Control and Prevention
in Fort Collins. Virus was passaged in Vero cell culture in order to provide
sufficient stock volume required to complete experimental infections. Supernatant
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was collected on days 3, 6 and 7 post-infection and viral titer of the resulting
stock was measured using the Reed-Muench method in 96-well TC plates. Stock
virus collected on day 3 during the Vero cell infections was used to conduct the
subsequent experimental infections in the primary cell lines. The viral titer of PR
ZIKV P5 stock day 3 was measured three times using the Reed-Muench method
and the results indicated an average viral titer of 1x106.65 infectious virions/ml.
Experimental Infections
As noted above, hepatocyte and PC cell cultures were passaged into 10
T-12.5 flasks and primary kidney cells were passaged into 10 T-25 flasks prior to
experimental infection. Kidney cells were passaged into larger flasks because of
issues with pelleting the cells that were observed during trial runs of the sample
collection method. The cells were incubated at 37oC with 5% CO2 and media
was exchanged every two days until the cultures were ready for the experimental
infections. Once the flasks were 85-90% confluent, they were separated into two
different treatment groups; 5 flasks for Mock (-K) infections and 5 flasks for the
experimental ZIKV infections. After the 10 primary cell cultures for each tissue
type reached 85-90% confluency, the culture media was removed, and cells were
washed using sterile 1X Dulbecco’s phosphate buffered saline. Five flasks from
each tissue type were used for ZIKV treatments. Each well was experimentally
infected with a 1:10 dilution of Stock PRVABC59 ZIKV isolate suspended in the
corresponding maintenance media (2 % fetal bovine serum (FBS) DMEM, 5%
FBS Vasculife, or 5% FBS F-12K). Flasks for each tissue type were treated as
controls and the cultures were mock inoculated with maintenance media only.
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The cells were rocked at 25oC for 1 hour to allow for viral adsorption. After
completion of the 1-hour adsorption period, ZIKV and mock media were removed
and replaced with 3 ml of maintenance cell culture media.
Sample Collection
Flasks containing the mock and ZIKV infected primary cell cultures were
trypsinized (0.025% Trypsin w/ EDTA) for 10 minutes at 37oC and then
mechanically dissociated with a cell scraper at 12, 24, 48, and 72 hours post
infection (hpi). Cell culture supernatant was also collected and frozen back at -4
o

C in 15 ml conical during the 72 hpi collection timepoint for future detection of

viral RNA in the culture suspension. Following mechanical dissociation, cells
were washed and collected in a 15-mL conical tube with 10% FBS DMEM (PC
and kidney) or hepatocyte wash media (hepatocytes). The collected cell
suspension was pelleted down at 500 x g for 10 minutes and the supernatant
was decanted. After the initial decanting, the cells were subsequently ran at 500
x g for 3 minutes to help pull the remaining media to the bottom of the conical
tube. Any remaining cell culture media was removed via a micropipette and
discarded to avoid any disruption of the RNA isolation process by media
components. The collected cell pellets were frozen back at -4 oC until cellular
RNA was extracted from the samples.
Ribonucleic Acid Extraction
and Detection of Viral
Ribonucleic Acid
Viral RNA was extracted from supernatant samples collected at the 72
hour post inoculation timepoint following the protocol outlined in the Omega
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E.Z.N.A viral RNA kits. The extracted viral RNA was reverse transcribed into
complementary DNA (cDNA) using the EPISCRIPT RNase H- RT kit with ZIKV
specific primers designed to amplify a conserved region of the ZIKV E protein
sequence. Prepared samples were run on a modified version of the RT
thermocycler program (optimized by Tyler Sherman). Sample mix 1 (template
and primers) was run at 94 oC for 1 minute, immediately placed on ice for 3
minutes, gently mixed with the RT master mix, and finally ran at 45 oC for 1hr and
30 minutes. The subsequent cDNA samples were employed in end point
Polymerase chain reaction (PCR) using the Quantabio Accustart II PCR
supermix with the same primer set used for cDNA synthesis. 5 ul of cDNA
template mixed with 20 ul of PCR MM (following Accustart II PCR supermix
protocol) in DNase and RNase free PCR tubes. Mixed samples were run on the
thermocycler program, ZIKV. The ZIKV program was optimized over multiple
trials for effective detection of viral RNA with the Accustart II Supermix kit. The
resulting PCR products were assessed for the presence of the viral RNA
sequences via gel electrophoresis on a 2% agarose gel containing Ethidium
Bromide. The PCR products were mixed with 5 ul of loading dye and loaded into
the predetermined agarose gel well. Two ladders were added to the outside wells
flanking the PCR product samples and the gel was run for 40 minutes at 110
volts, A sample with a band at the expected 362 bp PCR product size was
considered to be a positive result for ZIKV susceptibility in the corresponding cell
culture.
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Viral Titer Assay
Cell culture suspension from ZIKV treated 72 hour timepoint samples were
tittered following the widely accepted Reed Muench viral titer method. Vero E6
cells were cultured in a 96 well cell culture plate and allowed to grow to 85-95%
confluency at 37 oC with 5% CO2 prior to conducting the viral titer assay. ZIKV
treated 72 hour timepoint sample suspensions were serially diluted at a 1/10 ratio
(10-1 to 10-8) with 2% FBS DMEM (Vero E6 media) in autoclaved eppendorf
tubes. Serially dilute suspensions (100 ul) were aliquoted in to the 96 well plate in
descending order and incubated at 37 oC with 5% CO2 for 30 minutes to allow for
an adsorption period. A positive control of PR ZIKV stock virus suspension and a
negative control of cell culture suspension from the corresponding control 72
timepoint sample were also aliquoted into the first and last rows of the 96 well
plate. After completing the adsorption step, 150 ul of 2% FBS DMEM was added
to each well before placing the plates back into the incubator. Plates were
allowed to incubate for 9 days before being read out using the Reed Muench viral
titer calculation method. Viral titers were calculated as tissue culture infectious
dose 50 (TCID50) values using the appearance of cytopathic effect (CPE) in 72
hour timepoint sample wells as a positive result. See figure 2.2 for a visual
example of the marked difference between a well positive for CPE and a noninfected well.
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No CPE

CPE +

Figure 2.2: A comparison of a non-infected Vero E-6 well with a ZIKV
infected well. CPE is evident in the ZIKV infected well (right) marked by the
presence of clearing in the cell monolayer, increased amounts of dead cells
floating in suspension (dark rounded cells), and abnormal morphology of
remaining adherent cells.
Cellular Ribonucleic Acid Extraction and
Examination of Type I Interferon
Associated Genes
Omega E.Z.N.A Total RNA kits and corresponding kit protocol were used
to extract cellular RNA from the collected timepoint cell pellets. Viral RNA was
also collected from ZIKV treated timepoint samples by re-suspending the cell
pellet in 700 ul of the RTK lysis buffer (Total RNA kit lysis buffer) and splitting the
sample evenly into two 350 ul samples. From this point, RNA extraction of both
sample types (viral and cellular) was carried out following the protocol outlined in
the respective RNA isolation kits without any further alterations. Extracted RNA
samples were analyzed for genomic DNA, lysis buffer, and unwanted cellular
component contamination with a Thermo scientific Nanodrop 2000
Spectrophotometer. Contaminated samples, indicated by a 260/280 ratio value
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lower than 1.9 were cleaned with a sodium acetate clean up protocol (provided
by Dr. Karen Gomez’s lab). Cleaned RNA samples were retested on the
Nanodrop to ensure that the contamination issue had been resolved.
Nanodrop results also gave a relative concentration of RNA within each
samples, which was used to calculate the volume of RNA sample added in the
subsequent DNase treatment step. The volume of RNA sample added to each
DNase reaction was calculated to yield the Promega RQ1 RNase-free DNase
kit’s recommended RNA concentration of 2ug per reaction. Mixed DNase
reaction samples were aliquoted following the kits protocol with no alterations.
Samples were placed on the thermocycler and ran at 37 oC for 30 minutes,
placed on ice while adding 1ul of DNase STOP buffer, and finally ran at 65 oC for
10 minutes to end DNase enzyme activity. DNase treated samples were used for
complementary DNA (cDNA) synthesis within 30 minutes of completing the
treatment step. The immediate use of the treated RNA for cDNA was carried out
to decrease the degradation and loss of target cellular RNA from a freeze/thaw
cycle.
At this point in the PCR analysis, viral RNA and cellular RNA samples
diverged in their reaction kits and applications. Extracted viral RNA samples from
the 72 hour ZIKV treated cell pellets underwent cDNA synthesis using the same
EPISCRIPT RT kit and protocol outlined for the viral RNA suspension samples.
The resulting cell pellet cDNA samples were evaluated for the presence of ZIKV
RNA using the same ZIKV E primers, Accustart II PCR supermix kit with 5 ul of
cDNA template, and thermocycler program used to evaluate the viral RNA
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suspension samples. Resulting PCR products were evaluated for the presence of
ZIKV RNA in the same manner as the suspension with no alterations (2%
agarose gel w/ Ethidium Bromide ; 110 volts for 40 minutes).
DNase treated cellular RNA samples were reverse transcribed into cDNA
using a qScript cDNA supermix kit. Calculations for determining the volume of
DNase treated RNA added in for cDNA synthesis of each sample was based on
yielding a £ 1ug concentration of total cellular RNA per reaction. Synthesized
cellular cDNA from 72 hour timepoint samples were evaluated for the presence
and expression of Type I IFN associated gene transcripts through Semiquantitative PCR techniques. PCR was carried out on the 72 hour cDNA sample
with the Accustart II PCR supermix kit. PCR MM was aliquoted following the
Accustart supermix protocol (primer conc. at 200 nm), mixed thoroughly, and
then dispensed into each tube with a Thermofisher scientific electronic
multichannel equalizer pipette. A standard of 3 ul of cDNA from the 72 hour
timepoint samples (both control and treated) was mixed into the corresponding
PCR tube prior to being ran on the ImmuneGene program. The
annealing/elongation step temperatures were altered from the standard 60 oC for
b-actin and the AJ ISG15 (bat) primer set sample runs. Although B-actin, JAK1
and STAT1 levels were evaluated for the 72 hour timepoint samples from all
three animal, working primer sets for ISG15 and Oas1b were not available for all
three species. ISG15 was only evaluated in deer mice and Jamaican fruit bats,
and Oas1b was only evaluated in deer mouse and Syrian golden hamster
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samples. Resulting PCR products were run on a 2% agarose gel with EtBr in the
same manner as the viral RNA suspension and cell pellet samples.
Images were taken of the visualized PCR products and uploaded for band
density analysis using the image analysis software, FIJI.

Table 2.1: Thermocycler programs for PCR analysis.
Thermocycler Programs for PCR Analysis
Program

ZIKV

Immune Genes

Thermocycler

Bio-Rad MJ mini Thermal cycler

Bio-Rad T100 Thermal cycler

1: Initial denaturing
step

94 oC for 5 minutes

94 oC for 3 minutes

2: Cycle denaturing
step

94 oC for 1 minute

94 oC for 30 seconds

3: Annealing step

o

59 C for 30 seconds

B-actin: 59 oC
JAK1: 60 oC
STAT1: 60 oC
ISG15- AJ: 55 oC, DM: 60
o
C
Oas1b: 60 oC

4: Elongation step

72 oC for 30 seconds

5:Repeat steps 2 -4 #
of times

35x

35x

6: Hold at 4 oC

¥

¥

For 1
minute

Note: A visual comparison of the two thermocycler programs used with the
Accustart II PCR supermix kit to test samples for the presence of ZIKV RNA and
Type I IFN related immune genes (JAK1, STAT1, ISG15, and OAS1b with b-actin
as the reference gene). The annealing and elongation step of the immune gene
program are combined into a single step. Optimization trials indicated that
keeping the reaction at the optimal primer melt temp generates a cleaner PCR
product for a majority of the tested immune genes.
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Table 2.2: A list of the primer sequences and PCR product sizes for all
eight of the primer sets.
Reverse Primer
Sequence
(5’-3’)

Expected
Product
size

Opt.
melting
temp
(°C)

Gene

Gene Name

Forward Primer
Sequence
(5’-3’)

B-actin

Beta-actin

GCTACAGCT
TCACCACCACA

TCTCCAGGGA
GGAAGAGGAT

150

57

JAK1

Janus Kinase
1

TCAAATGCC
TGGCTCCCAT

TCATGGCATAG
TGGGAGATGG

107AJ/HAM
120-DM

60

STAT1
DM
&HAM

Signal
transducer and
activator of
transcription 1

ACGCCGTCA
TGTTGGATAAG

TGTTTCTGGT
CGTTCTTCGC

186

60

STAT1
AJ

Signal
transducer and
activator of
transcription 1

AGGTGCATTA
TGGGCTTCATC

TGTGAATGTG
ATGGCCCCTT

150

60

ISG15
DM

Interferon
stimulated
gene 15

TGGTGTCCC
TGACTAACTCC

TAACGCCCTCT
TGTAGCATC

130

60

ISG15
AJ

Interferon
stimulated
gene 15

GCTGCAGAG
CCCACATACAT

GTCCTCAAGC
AGCATGGACT

125

60

Oas1b

Oligoadenylate
synthase 1b

CAGTATGCC
CTGGAGCTGC

GTACTTGGTG
ACCAGTTCC

110

60

ZIKV
E
protein

ZIKV envelope
protein

GAGCATCCA
GCCAGAGAAC

GTGCGTCCTTG
AACTCTACC

362
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Note: The forward and reverse sequence optimized melting temp, and expected
base pair size for each of the selected primer sets is displayed in the table.
Differing expected PCR product sizes are listed with an acronym corresponding
to the species producing the different product size (AJ- bat, DM- deer mouse,
HAM- hamster). The PCR product size for ISG15 for hamster samples and
Oas1b for bat samples are not listed because working primers for the genes in
the animals were not available during the current study. Bp=base pair
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Statistical Analysis of Type I Interferon
Associated Immune
Gene Expression
The PCR product of each of the selected genes for a single tissue type of
each animal were ran in a set of 4 or 5 neighboring wells to observe the
expression of immune genes within a single primary cell type from one animal.
Control and ZIKV treated samples were also ran in parallel on the same row of a
gel to allow for the semi-quantitative analysis of the PCR product band density
between the different treatments. Gel images were taken on the Hawkinson lab
U.V. lightbox and then converted to a black and white image. Utilizing the image
analysis software FIJI, uploaded images of the immune gene PCR product gels
were formatted for band density analysis by converting the image to an 8-bit
format, inverting the black and white gradient, and adjusting the brightness and
contrast to increase the clarity of the image. The black and white gradients of the
image are inverted to allow for FIJI to quantify the relative levels of PCR product
by calculating the density of the band compared to either the light background or
another PCR product band. See figure 2.3 for a comparison between the original
B&W image and the FIJI converted image used for analysis.
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Figure 2.3: A comparison between the original immune gene PCR products
gel image from bat 7’s hepatocyte cell pellet RNA and the FIJI converted
image . The left image is the original and the right image is the FIJI converted
image. The first four bands (L to R) represent B-actin, JAK1, STAT1 and ISG15
for Bat 7 hepatocyte 72 hour control sample. The second set of bands represent
the same genes for Bat 7 hepatocytes’ 72 hour ZIKV treated sample.
PCR product band densities for the selected genes were calculated by
conducting the Gel Analyzer program in FIJI. The Gel analyzer program is a fourstep protocol that was carried out by highlighting the first band of interest and
designating it as the first lane (command + 1). After the first lane was selected,
the highlighted rectangle of the first band was dragged to the region of the
second band of interest. The second band of interest was designated as the
second lane (command + 2). Once both lanes were selected, the density of each
band was visualized by plotting the lanes (command + 3). The plotted lanes
were displayed as two different peaks in the same order as they were selected
(i.e. lane 1 was the top peak and lane two was the bottom peak). See figure 2.4
for an example of the plotted lanes from Deer mice 6’s b-actin densities in
hepatocyte cultures from both treatments. After plotting the lanes, the program
required the placement of a cutoff line.
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Once the cutoff line was drawn, the FIJI wand tool was used to display a
calculation of the relative area underneath the peaks.

Figure 2.4: The plotted lanes from DM 6’s b-actin densities in hepatocyte
culures. The plotted peaks represents the relative density of b-actin’s PCR
product in the control (top peak) and ZIKV treated (bottom peak) DM6
hepatocyte culture samples. The number present in each peak indicates the
percentage of the area under one of the curves compared to the area under the
other curves.
The final step of the Gel Analyzer program was selecting the label peaks
option in the analyze pulldown toolbar. The label peaks option displayed a
percent value of one peak’s area divided by the total area of both peaks.
The current study utilized the expected PCR product band size for each gene
with the FIJI program to calculate the percent densities of a control sample’s
selected gene compared to the same gene in the ZIKV treated sample. Table 2.2
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provides a list of all primer sequences and expected product sizes of primer sets
used in the current project. The peak areas and density comparison percentages
were compiled into a excel data sheet for statistical analysis in SAS.
Immune gene density percentages were all normalized to b-actin in excel
prior to running an analysis of variance (ANOVA) with SAS. Sources of variation
in the statistical model included treatment (control vs ZIKV), tissue type, species,
all possible interactions and residual error. If main effects or interactions were
significant, lsmeans were compared using a pairwise t-test with the PDIFF option
in SAS.
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CHAPTER III
RESULTS
Establishment of Primary Cell Lines
Establishing liver, kidney, and lung primary cell lines from all three
selected animal models was attempted in multiple trials using previously
developed standard operating procedures (SOP). While this was successful for
lung and kidney primary cell cultures, culturing primary deer mouse and
Jamaican fruit bat hepatocytes required the development of new SOP during this
project. Liver, lung, and kidney primary cell cultures, designated as pulmonary
cell, kidney cell, and hepatocyte cultures were successfully established from 3
sets of biological replicates in deer mice and Jamaican fruit bats. Primary
pulmonary cell cultures were the only cell line successfully established in Syrian
golden hamsters. Hepatocytes were successfully isolated from the hamsters
using the developed SOP, but cells did not stay viable in culture for long enough
to be utilized in experimental ZIKV infections. The absence of successfully
established hepatocytes cultures derived from hamster is attributed to the lack of
sufficient media type and required growth factors for culturing the cell lines in an
extended timeline. Between the three established cell lines, the hepatocytes
were the only cell lines that presented with differing morphologies during culture
period. Figure 4 shows images of deer mouse hepatocytes from the initial
seeding to day 12 post inoculation. No notable differences were observed
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between cell morphology of the same cell line between animals. Twenty-one total
sets of primary cell lines were successfully established from 3 biological
replicates of each animal model (7 different cell lines) for use in ZIKV
experimental infection. Table 3.1 shows established primary cell lines for each
animal.

Table 3.1: A visual representation of established primary cell lines.
Pulmonary cells
(Lung tissue)

Mixed kidney
(kidney tissue)

Hepatocytes
(Liver tissue)

Deer mice
(Peromyscus
maniculatus)

3 sets

3 sets

3 sets

Jamaican fruit bats
(Artibeus
jamaicensis)

3 sets

3 sets

3 sets

Syrian golden
hamsters
(Mesocricetus
auratus)

3 sets

X

X

Note: Primary cell lines were established from the three selected animal models
in the current study. An X represents the lack of primary cell cultures derived
from an animal and/or tissue type. Total n= 21 primary cell cultures.
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Day of Initial isolation

Day 1 post inoculation

Day 2 post inoculation

Day 12 post inoculation

Figure 3.1: Timeline images of primary deer mouse hepatocytes from initial
isolation to day 12 post inoculation. Images were taken on an inverted light
microscope at 20x magnification. Notable differences in morphology between
each timepoint show the progression of the morphology change in the primary
hepatocytes that has been noted multiple times in previous studies/methods
papers employing mouse and rat primary hepatocyte cultures.
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Viral Titer of Cell Culture
Suspension
The viral titer of ZIKV treated cell culture suspension from the 72 hour
timepoint of each established primary cell line was determined using the Reed
Muench viral titer method. Of the 21 tested samples, only 6 samples showed
detectable levels of infectious ZIKV. An average tissue culture infectious dose 50
TCID50 of 1x102.47 infectious virions per ml was calculated between the 6
samples with detected virus. Infectious virus was detected in all three hamster
pulmonary cell cultures, and deer mouse 6, Bat 5, and 6 hepatocyte cultures.
Table 4 includes calculated TCID50s.
Detection of Viral Ribonucleic Acid
in 72 Hour Cell Pellet and
Suspension Sample
The cell pellet and suspension of ZIKV treated cell cultures were tested for
the presence of viral RNA through endpoint Polymerase Chain Reaction (PCR)
with a ZIKV specific primer set designed against a conserved region (within the
ZIKV Asian lineage) of the E protein sequence. Positive results showed a 362 bp
PCR product visualized on a 2% agarose gel. 72 hour cell pellet samples from all
of the established cell lines (n=21) were positive for ZIKV RNA. Two PCR
reactions (replicates) were run on each cell pellet sample and no differences in
PCR product bands were present between the replicates. Figure 3.2 displays the
completed ZIKV RNA PCR products of the 72 hour cell pellet samples visualized
on a 2% agarose gel.
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362 bp

400 bp
300 bp

362 bp

400 bp
300 bp

Figure 3.2: Gel image of ZIKV treated cell pellet samples. The PCR products
ran on the gel with a band at the same size as the +K (PR ZIKV stock virus
cDNA) are confirmed for the presence of ZIKV RNA in the cell pellet. Every one
of the 21 collected RNA samples (RT to cDNA) from 72 hour ZIKV treated cell
pellets were positive for the expected 362 bp product. The unexpected positive
result of the Bat 1 PMVEC non-infected control sample was resolved after
resynthesizing the cDNA and re-running the sample with PCR. It was determined
that contamination occurred during the first cDNA synthesis with contaminated
primers.
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PCR analysis of the 72 hour ZIKV treated suspension samples indicated
that 19 of the 21 samples tested positive for ZIKV RNA in at least one of the
replicates. Figure 3.3 displays the completed PCR products for all of the 72 hour
bat primary cell culture suspension samples visualized on a 2% agarose gel.
Hepatocyte culture suspension derived from bat 7 and kidney cell suspension
derived from deer mouse 10 did not produce a positive result in either replicates.
Within the 19 positive suspension samples, only 3 samples tested positive for
ZIKV RNA in 1 of the 2 replicates. The three samples indicating only 1 positive
result for ZIKV RNA include pulmonary cell culture suspension derived from deer
mouse 3 and 4, and hepatocyte culture suspension derived from deer mouse 7.
Ultimately, 16 samples tested positive twice for ZIKV RNA and 5 of the samples
had detectable levels of infectious virus in the cell pellet. Interestingly, all of the
hamster suspension samples and all but one of the bat suspension samples
tested positive for ZIKV RNA during both trials. Deer mouse primary cell cultures
were the only samples that did not consistently test positive for ZIKV RNA
between replicates. Table 3.2 shows detected viral RNA aligned with detected
viral titers in the 72 hour ZIKV treated cell culture suspension samples.
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362 bp

400 bp
300 bp

362 bp

400 bp
300 bp

Figure 3.3: Gel image of ZIKV treated Bat cell suspension samples. The
PCR products ran on the gel with a band at the same size as the +K (PR ZIKV
stock virus cDNA) are confirmed for the presence of ZIKV RNA in the cell culture
suspension. Bat cell culture PCR products displayed on the gel indicate that Bat
1, 2, and 3 pulmonary cell, Bat 5 and 6 hepatocyte, and Bat 1, 2, and 4 kidney
cell culture suspensions were positive for ZIKV RNA. As expected, Bat Kidney
and Bat 5 hepatocyte non-infected control samples did not indicate the presence
of the expected 362 bp PCR band. Unexpectedly, the hamster 3 pulmonary cell
culture non-infected control suspension did indicate a positive result. The
problematic false positive was resolved after resynthesizing the cDNA and rerunning the sample with PCR. It was determined that contamination occurred
during the first cDNA synthesis with contaminated primers.
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362 bp

400 bp
300 bp

Figure 3.4: Gel image of re-run false positive negative controls. All of the
false negative results were resolved for the samples except for the non-treated
(-K) PC cells derived from Bat 1. Interestingly, all of the bat -K samples indicated
an light band at the expected PCR product size. Potential reasons for the
unresolved false positives in the bat samples will be addressed in the discussion.
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Table 3.2: A comparison of viral RNA and infectious virus detected in
suspension samples.
Sample ID
B1 PC
B2 PC
B3 PC
B1 KID
B2 KID
B4 KID
B5 HEP
B6 HEP
B7 HEP
DM 3 PC
DM 4 PC
DM 7 PC
DM 6 KID
DM 7 KID
DM 10 KID
DM 6 HEP
DM 7 HEP
DM 10 HEP
HM 1 PC
HM 2 PC
HM 3 PC

Viral RNA detected in
susp
100 %
100 %
100%
100%
100%
100%
100%
100%
0%
50%
100%
50%
100%
100%
0%
100%
50%
100%
100%
100%
100%

Viral titer
ND
ND
ND
ND
ND
ND
1x10^2.58
1x10^2.58
ND
ND
ND
ND
ND
ND
ND
1x10^2.58
ND
ND
1x10^2.26
1x10^2.58
1x10^2.26

Note: The samples listed in the table are ZIKV treated 72 hour cell suspension
samples tested for viral RNA and infectious virus using endpoint PCR and Reed
Muench viral titer assay methods. The value listed in the viral RNA column is the
percentage of times the sample displayed a band at the expected PCR product
size (362 bp) over two trials (i.e. 2/2 =100%). The TCID50 value is listed as
virions per ml. ND= Not detectable.
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Examination of Type I Interferon
Associated Genes
Established cell cultures from all three animal models were treated with
either a control of 2% FBS DMEM or a 1:10 dilution of ZIKV stock virus and
incubated for 72 hours prior to sample extraction to compare the effects of ZIKV
infection on JAK1, STAT1, ISG15, and Oas1b expression levels in parallel with a
non-infected control. Data collected on the expression levels, of all four genes
normalized to b-actin are shown in figure 7, 8 and 9. It is important to note, as
expected, b-actin expression did not show any significant fold changes between
the different treatments in any of the cell lines.
Deer mouse cell cultures displayed the most extensive amount of
significant gene expression level changes between treatments within the
selected Type I IFN associated genes. The ZIKV treated samples in all three
Deer mouse cell culture lines exhibited a highly significant upregulation in JAK1,
STAT1, ISG15 and Oas1b. ZIKV treatment induced a 3.3 fold increase in JAK1
(P < 0.0001), 16.6 fold increase in ISG15 (P < 0.0001), and a 5.7 fold increase in
Oas1b (P=0.0253) steady-state mRNA levels compared to the basal levels in
control samples. However, no difference was detected in steady-state mRNA
levels between the ZIKV treatment and control for STAT1 in pulmonary cells
derived from all three deer mice. ZIKV treatment induced a nearly 5 fold increase
in STAT1 (P= 0.0027), 2.9 fold increase in ISG15 (P= 0.0035), and a 5.8 fold
increase in Oas1b (P < 0.0001) steady-state mRNA levels of kidney cells derived
from all three deer mice compared to the basal levels observed in control
samples. However no difference was detected in steady-state mRNA levels of
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JAK1 between the ZIKV treatment and control in kidney cells derived from all
three deer mice. Lastly, ZIKV treatment induced a nearly 3 fold increase in
STAT1 (P= 0.312), nearly 10 fold increase in ISG15 (P < 0.0001), and a 16.2 fold
increase in Oas1b (P= 0.0002) steady-state mRNA levels in hepatocytes derived
from all three deer mice compared to the basal levels observed in control
samples. No difference was detected in JAK1 steady-state mRNA levels of
hepatocytes derived from all three deer mice. Figure 3.5 visualizes the
differences in steady-state mRNA levels of JAK1, STAT1, Oas1b, and ISG15 for
the deer mouse primary cell cultures.
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Figure 3.5a: Expression levels of JAK1, STAT1 for Deer mouse samples.
Graphs display effects of ZIKV treatment on expression of the selected Type I
IFN associated gene, JAK1, in established primary cell cultures derived from
deer mice. ZIKV samples were treated with a 1:10 PR ZIKV stock dilution in cell
culture media (cell line dependent) and control (-K) samples were treated with
cell culture media only. Synthesized cDNA from total cell RNA samples at the 72
hour timepoint for the control and ZIKV treated samples were ran in semiquantitative PCR for each gene. ZIKV treated sample normalized PCR product
density values are represented as blue bars (n= 3 per graph) and control sample
values are represented by the orange bars (n= 3 per graph). Control and ZIKV
treated sets with a single asterisk (*) indicate a significant p value (0.5 to 0.1) and
sets with three asterisks indicate a highly significant p value (< 0.01) in steadystate mRNA levels between treatments. The value in the white box to the right of
each set of sample bar graphs indicates the fold change in steady-state mRNA
levels between the control and ZIKV treated sample.
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Figure 3.5b: Expression levels of STAT1 for Deer mouse samples. Graphs
display effects of ZIKV treatment on expression of the selected Type I IFN
associated gene, STAT1, in established primary cell cultures derived from deer
mice. ZIKV samples were treated with a 1:10 PR ZIKV stock dilution in cell
culture media (cell line dependent) and control (-K) samples were treated with
cell culture media only. Synthesized cDNA from total cell RNA samples at the 72
hour timepoint for the control and ZIKV treated samples were ran in semiquantitative PCR for each gene. ZIKV treated sample normalized PCR product
density values are represented as blue bars (n= 3 per graph) and control sample
values are represented by the orange bars (n= 3 per graph). Control and ZIKV
treated sets with a single asterisk (*) indicate a significant p value (0.5 to 0.1) and
sets with three asterisks indicate a highly significant p value (< 0.01) in steadystate mRNA levels between treatments. The value in the white box to the right of
each set of sample bar graphs indicates the fold change in steady-state mRNA
levels between the control and ZIKV treated sample.
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Figure 3.5c: Expression levels of ISG15 for Deer mouse samples. Graphs
display effects of ZIKV treatment on expression of the selected Type I IFN
associated gene, ISG15, in established primary cell cultures derived from deer
mice. ZIKV samples were treated with a 1:10 PR ZIKV stock dilution in cell
culture media (cell line dependent) and control (-K) samples were treated with
cell culture media only. Synthesized cDNA from total cell RNA samples at the 72
hour timepoint for the control and ZIKV treated samples were ran in semiquantitative PCR for each gene. ZIKV treated sample normalized PCR product
density values are represented as blue bars (n= 3 per graph) and control sample
values are represented by the orange bars (n= 3 per graph). Control and ZIKV
treated sets with a single asterisk (*) indicate a significant p value (0.5 to 0.1) and
sets with three asterisks indicate a highly significant p value (< 0.01) in steadystate mRNA levels between treatments. The value in the white box to the right of
each set of sample bar graphs indicates the fold change in steady-state mRNA
levels between the control and ZIKV treated sample.
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Figure 3.5d: Expression levels of Oas1b for Deer mouse samples. Graphs
display effects of ZIKV treatment on expression of the selected Type I IFN
associated gene, Oas1b, in established primary cell cultures derived from deer
mice. ZIKV samples were treated with a 1:10 PR ZIKV stock dilution in cell
culture media (cell line dependent) and control (-K) samples were treated with
cell culture media only. Synthesized cDNA from total cell RNA samples at the 72
hour timepoint for the control and ZIKV treated samples were ran in semiquantitative PCR for each gene. ZIKV treated sample normalized PCR product
density values are represented as blue bars (n= 3 per graph) and control sample
values are represented by the orange bars (n= 3 per graph). Control and ZIKV
treated sets with a single asterisk (*) indicate a significant p value (0.5 to 0.1) and
sets with three asterisks indicate a highly significant p value (< 0.01) in steadystate mRNA levels between treatments. The value in the white box to the right of
each set of sample bar graphs indicates the fold change in steady-state mRNA
levels between the control and ZIKV treated sample.
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In contrast to deer mouse cultures, Jamaican fruit bat cultures had the
lowest amount of significant expression changes in steady-state mRNA levels of
the selected Type I IFN associated genes between the three animal models. The
ZIKV treatment in all three Jamaican fruit bat cell culture lines did not induce any
significant increases in JAK1, STAT1, ISG15 and Oas1b steady-state mRNA
levels. The largest fold change observed in the bat samples was a nearly 2 fold
increase of STAT1 steady-state mRNA levels in hepatocytes derived from all
three bats. However, t-test statistical analysis of the hepatocyte STAT1 fold
change between the ZIKV treatment and control yielded a non-significant P value
(P= 0.0793). Figure 3.6 visualizes the differences in steady-state mRNA levels of
JAK1, STAT1 and ISG15 for the Jamaican fruit bat primary cell cultures.
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JAK1 levels in Bat primary cell cultures
Normalized Density of PCR product in %
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0.9
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ZIKV
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Figure 3.6a: Expression levels of JAK1 for Jamaican fruit bat samples.
Graphs display effects of ZIKV treatment on expression of the selected Type I
IFN associated gene, JAK1, in established primary cell cultures derived from
bats. ZIKV samples were treated with a 1:10 PR ZIKV stock dilution in cell culture
media (cell line dependent) and control (-K) samples were treated with cell
culture media only. Synthesized cDNA from total cell RNA samples at the 72
hour timepoint for the control and ZIKV treated samples were ran in semiquantitative PCR for each gene. ZIKV treated sample PCR product density
values (normalized to b-actin) are represented as blue bars (n= 3 per graph) and
control sample values are represented by the orange bars (n= 3 per graph).
Control and ZIKV treated sets with a single asterisk (*) indicate a significant p
value (0.5 to 0.1) and sets with three asterisks indicate a highly significant p
value (< 0.01) in the difference of steady-state mRNA levels between treatments.
The value in the white box to the right of each set of sample bar graphs indicates
the fold change in steady-state mRNA levels between the control and ZIKV
treated sample.
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Figure 3.6b: Expression levels of STAT1 for Jamaican fruit bat samples.
Graphs display effects of ZIKV treatment on expression of the selected Type I
IFN associated gene, STAT1, in established primary cell cultures derived from
bats. ZIKV samples were treated with a 1:10 PR ZIKV stock dilution in cell
culture media (cell line dependent) and control (-K) samples were treated with
cell culture media only. Synthesized cDNA from total cell RNA samples at the 72
hour timepoint for the control and ZIKV treated samples were ran in semiquantitative PCR for each gene. ZIKV treated sample PCR product density
values (normalized to b-actin) are represented as blue bars (n= 3 per graph) and
control sample values are represented by the orange bars (n= 3 per graph).
Control and ZIKV treated sets with a single asterisk (*) indicate a significant p
value (0.5 to 0.1) and sets with three asterisks indicate a highly significant p
value (< 0.01) in the difference of steady-state mRNA levels between treatments.
The value in the white box to the right of each set of sample bar graphs indicates
the fold change in steady-state mRNA levels between the control and ZIKV
treated sample.
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ISG15 levels in Bat primary cell lines
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Figure 3.6c: Expression levels of ISG15 for Jamaican fruit bat samples.
Graphs display effects of ZIKV treatment on expression of the selected Type I
IFN associated gene, ISG15, in established primary cell cultures derived from
bats. ZIKV samples were treated with a 1:10 PR ZIKV stock dilution in cell
culture media (cell line dependent) and control (-K) samples were treated with
cell culture media only. Synthesized cDNA from total cell RNA samples at the 72
hour timepoint for the control and ZIKV treated samples were ran in semiquantitative PCR for each gene. ZIKV treated sample PCR product density
values (normalized to b-actin) are represented as blue bars (n= 3 per graph) and
control sample values are represented by the orange bars (n= 3 per graph).
Control and ZIKV treated sets with a single asterisk (*) indicate a significant p
value (0.5 to 0.1) and sets with three asterisks indicate a highly significant p
value (< 0.01) in the difference of steady-state mRNA levels between treatments.
The value in the white box to the right of each set of sample bar graphs indicates
the fold change in steady-state mRNA levels between the control and ZIKV
treated sample.
Similar to the deer mice, hamster samples displayed a highly significant
difference in the expression of two out of the three examined Type I IFN
associated genes. ZIKV treatment induced a nearly 5 fold increase in JAK1 (P <
0.0095) and a 3.3 fold increase in Oas1b (P < 0.00052) steady-state mRNA
levels of pulmonary cells derived from all three hamsters compared to the basal
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levels observed in control samples. However, no difference was detected in
STAT1’s steady-state mRNA levels between the ZIKV treatment and control for
pulmonary cells derived from all three hamsters. Figure 3.7 visualizes the
differences in steady-state mRNA levels of JAK1, STAT1 and Oas1b for the
Syrian golden hamster pulmonary cells.
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Figure 3.7: Expression levels of JAK1, STAT1, and Oas1b for Syrian golden
hamster samples. Graphs display effects of ZIKV treatment on expression of
the selected Type I IFN associated genes in primary pulmonary cell cultures
derived from hamsters. ZIKV samples were treated with a 1:10 PR ZIKV stock
dilution in cell culture media(cell line dependent) and control (-K) samples were
treated with cell culture media only. Synthesized cDNA from total cell RNA
samples at the 72 hour timepoint for the control and ZIKV treated samples were
ran in semi-quantitative PCR for each gene. ZIKV treated samples PCR product
density values (normalized to b-actin) are represented as blue bars (n=3 per
graph) and control sample values are represented by the orange bars (n=3 per
graph). Control and ZIKV treated sets with a single asterisk (*) indicate a
significant p value (0.5 to 0.1) and sets with three asterisks indicate a highly
significant p value (< 0.01) in steady-state mRNA expression levels between
treatments. The value in the white box to the right of each set of sample bar
graphs indicates the fold change in steady-state mRNA levels between the
control and ZIKV treated sample.
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CHAPTER IV
DISCUSSION & CONCLUSION
Discussion
The Type I Interferon (IFN) response’s potent restriction on flaviviral
invasion and replication has been characterized in multiple previous studies
involving multiple host species [20, 133, 134]. In order to combat the restrictive
effects of the suppressive effects of the Type I IFN response, Flaviviruses have
evolved a relatively extensive number of species specific mechanisms using a
combination of the sfRNA and NS proteins to subvert the deleterious effects of
the host’s innate immune system response [2, 15, 30, 78, 135]. Zika virus (ZIKV),
a newly emerging member of the flavivirus family, has also demonstrated the
capacity to effectively repress the Type I IFN response in human and non-human
primates [3, 30, 93]. ZIKV has been shown to utilize the NS1, NS2B-3 complex,
NS4B, and NS5 proteins in combination with the sfRNA to mediate its subversion
of the host cell response. In consideration of the employed ZIKV non-structural
proteins, NS5’s influence on the expression of Type I IFN associated interferon
stimulated genes (ISG) has been the most clearly elucidated in previous ZIKV
research [2, 80, 93]. The reasoning behind the extensive amount of research into
ZIKV’s NS5 activity is founded by the necessity of the NS5 protein’s effective
antagonism on the phosphorylation of the host cell’s STAT2 to generate a
productive ZIKV infection [95]. STAT2 is an important signal transduction protein
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in the Type I IFN pathway that promotes the induction of hundreds of ISGs [81].
In humans, the STAT2 protein is effectively antagonized by proteosomal
degradation mediated through the interaction of the ZIKV NS5. In contrast, the
mouse STAT2 protein structure differs enough from the human counterpart to
resist degradation by the ZIKV NS5 protein [93]. The resistance of the mouse
STAT2 protein to NS5 antagonism allows for the induction of a robust type I IFN
response in host cells generating a highly protective immune response that
significantly limits ZIKV replication [3]. Therefore, current research studies
involving ZIKV have predominantly used the widely accepted Type I IFN
immunodeficient mouse model to study viral pathogenicity and test vaccine
candidates [27, 41, 95]. However, the use of an animal model without a complete
IFN response creates a number of concerns regarding the findings of the studies
in their application to animals with intact immune responses, such as humans. As
well, previous research has elucidated the relationship between ZIKV’s capacity
to suppress the host cell immune response in humans, non-human primates, and
mice, but a significant lack of insight into the antagonistic effects of ZIKV on the
host cell response in a diversity of mammalian species currently exists. In the
current study, we supplement the lack of data regarding the susceptibility and
host cell immune response of primary cell lines derived from three
immunocompetent animal models to ZIKV infection. We also provide the pilot
data to warrant further research into the development of two novel
immunocompetent disease models for vaccine and ZIKV pathogenicity work.
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During the current study, 7 different primary cell lines were derived from
Syrian golden hamsters, Jamaican fruit bats, and deer mice. Of the established
cell lines, research conducted with primary hepatocyte cell cultures from deer
mice and Jamaican fruit bats has not been published in any research papers to
date. In order to establish the primary hepatocyte cell lines, a protocol was
designed and optimized for isolating and culturing the selected cell type using the
widely accepted two-step liver perfusion method developed for rat hepatocyte
isolation as a foundation [130]. The developed protocol has shown consistency in
yielding high concentrations of viable hepatocytes from all three animal models.
However, further research into the optimal media type for hamsters is required to
culture hamster hepatocytes for longer than a week. Notable differences in
hepatocyte morphology in both deer mouse and Jamaican fruit bat cell lines in
prolonged cultures indicate the potential loss of hepatic phenotype functions such
as production of metabolizing enzymes and transport systems mentioned in
previous studies involving rat and mouse hepatocytes [122, 128]. It would be
beneficial for future studies to investigate which hepatocyte functions are lost in
cell culture. However, even with the potential loss of certain functions, the deer
mouse and bat hepatocytes established in this study still provided a sufficient
model for investigating the aims of the current study.
The investigation of susceptibility, and permissiveness to replication of
ZIKV in primary cell cultures from the selected animal models yielded surprising
results in consideration of previous research. We show that all 21 of the
established primary cell lines were susceptible to ZIKV infection through the
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presence of viral RNA in ZIKV treated cell pellet samples. Viral RNA was also
present in the suspension of 8 out of 9 bat cell cultures, 8 out of 9 deer mouse
cell cultures, and 3 out of 3 hamster cell cultures. Within the deer mouse
cultures, 3 out of the 8 infected cell culture suspensions only tested positive for
viral RNA in 50% of the conducted Polymerase Chain Reaction (PCR) assays (2
replicates). The ZIKV primer set employed for viral Ribonucleic Acid (RNA)
detection was has exhibited the capacity to detect viral RNA at a 1x106 dilution of
stock virus, indicating a relatively high sensitivity for the viral RNA. Therefore, we
conclude that the inconsistent results were most likely due to extremely low
concentrations of viral RNA possibly due to a restriction in the shedding of ZIKV
from host cells in the tested samples. The results of the cell culture suspension
and cell pellet testing for ZIKV RNA indicate that at least 16 of the 19 primary cell
cultures are susceptible to viral infection, permissive to ZIKV replication and
shedding of virions in suspension. It is also important to note that Jamaican fruit
bat non-treated suspension samples indicated very light bands at the expected
ZIKV PCR product size throughout ZIKV RNA testing. We believe the consistent
detection of false positives in bat samples may be caused by unexpected
annealing on bat cell mRNAs. A NCBI blast of the ZIKV PCR primer against the
recently sequenced Artibeus jamaicensis genome resulted in multiple sequence
alignments with 98% homology or higher. Therefore, the unexpected false
positives may be a result of unexpected mispriming on bat mRNA resulting in a
PCR product at a similar size as the expected ZIKV RNA product. Primers for the
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detection of ZIKV RNA in bat samples would either need to be optimized from the
current set or redesigned to alleviate the false positive issues.
The current study also supplemented the results of detected viral RNA in
suspension by testing ZIKV treated cell suspensions for levels of infectious virus
to determine the permissiveness of host cells for shedding infectious virus. We
show that 6 primary cell culture samples have detectable levels infectious virus in
their suspension. The most surprising result within these findings was the
detected of infectious virus deer mouse 6’s hepatocyte culture. Infectious virus
was also detected in two bat cell lines, bat 5 and 6 hepatocytes, and all three of
the Syrian golden hamster cultures. Considering the detectable levels of viral
RNA and infectious virus in suspension, the lack of consistent detection of viral
RNA and not detecting infectious virus in deer mouse pulmonary and kidney cells
may indicate insight into the tissue tropism of ZIKV in deer mice. ZIKV was able
to efficiently replicate and be shed into the suspension of the hepatocyte cells
derived from deer mouse 6 in high enough titers to be detected in the viral titer
assays. These results may indicate ZIKV’s tropism for hepatocytes in deer mice.
Similar to the deer mouse samples, infectious virus was only isolated in bat
hepatocyte culture, which may indicate a tropism for hepatocytes in bat as well.
However, further research involving in vivo work with deer mice and bats would
be required to confirm these proposed notions derived from these findings. Aside
from the consideration of tissue tropism, these results may provide an interesting
insight into the differences between animals of the same species in their
permissiveness to ZIKV infection. Besides hamster pulmonary cell cultures, the
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detection of infectious virus was varied between biological replicates in the same
cell culture tissue type. The differences between biological replicates could be
caused different alleles expressed in important ZIKV restrictive immune genes
between individuals in the same species. However, as with the tissue tropism
hypothesis, future research would need to investigate the effects of allelic
differences within a population of the samples species on flaviviral replication to
provide support for the proposed notion.
Our findings on the primary cell culture are consistent with previous in vivo
ZIKV research demonstrating the susceptibility and seroconversion of Jamaican
fruit bat and Syrian golden hamsters [96, 117]. However, we were surprised to
find that deer mouse derived primary cell lines were positive for ZIKV RNA in a
majority of the suspensions samples as well as testing positive in all of the cell
pellet samples. These results seemingly contradict the findings of Regina et al.’s
work with ZIKV and deer mice. The previous research study inoculated a
diversity of species with two ZIKV isolates and found that virus was not
detectable in sera and detectable levels of neutralizing antibodies were absent
[108]. The differences in Regina et al.’s results and the current study’s findings
may be attributed to the animal level (in vitro versus in vivo) that the studies were
conducted at. A considerable drawback of conducting virus research in vitro is
the lack of immune cells and the humoral branch of the immune response.
Therefore, it is possible that deer mouse primary cell cultures may be susceptible
to ZIKV infection in vitro, but a whole animal model is able to generate a
sterilizing innate immune response. Another marked difference between the two
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studies was the source of the deer mice employed in each study. Regina et al.’s
work involved wild caught deer mice whereas the current study utilized deer mice
from UNCO’s colony housed in HEPA-filtered cages. Multiple recent research
studies evaluating the immune response of multiple species of wild caught rodent
species (mainly rats and mice) compared to their laboratory raised “clean room”
counter parts yielded data supporting the presence of significant differences
between the wild caught rodents ability to mediate and clear pathogens
compared to the “clean room” rodents [136]. The noted differences in immune
responses between wild caught rodents and lab rodents may provide an answer
to the differences in susceptibility and permissiveness to replication observed
between our results and Regina et al.’s findings, but further research would be
required to provide evidence for the proposed notion.
The data yielded from the semi-quantitative PCR analysis of Type I IFN
associated immune expression provides noteworthy insights into the immune
response of all three animal models. Deer mouse samples displayed the greatest
number of significant fold changes across all tissue types in all of the examined
genes between treatments, aside from JAK1. These findings support the results
indicating that deer mouse primary cell lines were susceptible to ZIKV infection.
The robust induction of STAT1, ISG15 and Oas1b indicated by the large fold
changes of expression (3, 10, and 9 respectively) between treatments in all three
tissue types shows that the Type I IFN response is being triggered by an RLR,
most likely RIG-I, and the pathway is activated to the level of ISG expression.
The strong induction of the Oas1b and ISG15, two ISGs noted in previous
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research for their potent anti-flaviviral effects, provides evidence that the deer
mouse STAT2 is not being effectively antagonized by the ZIKV NS5 protein and
can therefore complete the downstream activation of ISGs. These findings
denote a unique outcome of ZIKV infections in deer mice that has not been
characterized in any animal model to date. It is possible considering the outcome
of the experimental infections, that deer mice could act as a reservoir model for
ZIKV future research.
The gene expression results of the Jamaican fruit bat primary cell cultures
show a stark contrast in fold change induction relative to the deer mouse
samples. Only one observed fold increase in gene expression occurred in all of
the tested bat samples. Bat hepatocytes indicated a 2-fold increase in STAT1
expression, but the change was determined insignificant after the conducting
statistical analysis. The lack of a observed fold changes in the bat Type I IFN
response associated genes in combination with the detection of ZIKV RNA in all
but one bat primary cell culture (B7 hepatocyte), suggests that Jamaican fruit
bats are susceptible to ZIKV infection and are not significantly upregulating the
expression of JAK1, STAT1, or ISG15 in response to viral infection. There are
three possible causes for the lack of increased ISG expression in the bat
samples. Considering the well-established insights into flaviviral Type I IFN
immune suppression bat cell, RLRs may be detecting viral epitopes and
activating the signaling pathway, but ZIKV is able to effectively antagonize a vital
signaling protein to suppress upregulation of ISGs. The effective antagonism of
the bat Type I IFN response may be produced at the level of STAT2 mediated by
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the ZIKV NS5 protein or at another step in the pathway that is unique to
Jamaican fruit bats. It is also possible that the lack of an observable fold change
in ISG15 may be due to bat cells constitutively expressing relatively high levels of
IFN-a and a subset of ISGs. A recent study by Zhou et al. indicates that
Australian black flying fox kidney cell lines (Pteropus alecto) constitutively
express high levels of IFN-a sequences in comparison to human HEK293T cells
and the expression levels of the IFN-a gene is not significantly upregulated in
response to viral infection by Hendra virus, Pulau virus (PulV), and Sendai virus.
Along with IFN-a, levels of Type I IFN genes including Oas1, MX1 and ISG15
were shown to have high constitutive expression in normal bat cells [137]. These
findings suggest that bats may be constitutively expressing high levels of potent
antiviral ISGs that are able to restrict high levels of viral replication while also
eliminating the need for a robust Type I IFN response in order to clear a viral
infection. Lastly, bat cell lines may be activing the Type III IFN pathway in
response to ZIKV infection, instead of the expected Type I IFN response. Unlike
human and mouse cells, black flying fox cells have been shown express Type III
IFN receptors on a wide variety of tissue types. The Type III IFN response was
also shown to be preferentially activated following experimental infection with
Tioman virus (Paramyxovirus) in black flying fox splenocytes. In contrast, the
Type I IFN response was shown to be downregulated during the experimental
infection in the splenocytes [138]. Within the same study, Zhou et al.
demonstrated that induction of the Type III IFN response, specifically PaFeTO5
cells treated with IFN-λ2, were effectively protected against PulV (Orthoreovirus)
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growth and pathology. The authors utilized PulV instead of Tioman virus to
demonstrate the antiviral qualities of the Type III IFN response, because PulV
displays observable CPE in PaFeTO5 cells [139]. However, these unique
characteristics of black flying fox cells have not yet been demonstrated across
multiple bat species. Although the discussed explanations for the lack of a strong
ISG induction in the Jamaican fruit bat cells are drawn from previous research in
bat cells, an extensive amount of research into elucidating the Type I and Type III
IFN response in Jamaican fruit bats is necessary before generating any traction
for the proposed reasoning.
Due to the lack of kidney cell and hepatocyte cell lines, the gene
expression results for the Syrian golden hamster is considerably limited in its
findings compared to the deer mice and Jamaican fruit bats. Despite the
limitations of only examining one cell culture type, the data yielded from the
hamster primary pulmonary cell lines indicates that JAK1 had a significantly
higher up-regulation in hamster pulmonary cell lines compared to the deer mouse
cell lines (5 fold and 3.3 fold, respectively). Interestingly, Oas1b only had a
moderate upregulation compared to the deer mice pulmonary cell lines (3.3 and
5.7, respectively). These findings taken with the results of the ZIKV RNA and
viral titer detection assays indicate that Syrian golden hamsters are susceptible
to ZIKV infection and it is postulated that the Type I IFN response is suppressed
by ZIKV at some point between JAK1 and the induction of ISGs effectively
limiting their expression.
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Conclusions
This pilot study has provided data to support further research into all three
animal models for ZIKV research. Each animal model displayed a unique
outcome in response to ZIKV infection compared not only the other animals in
the study, but also to humans and immunocompetent lab mice. As discussed in
the introduction, a robust induction of ISGs is inhibited by ZIKV NS5 in humans.
The inhibition of ISG production in humans allows for ZIKV to efficiently replicate
and generate a productive infection in human cells. However, immunocompetent
lab mice’s ISG induction is not effectively suppressed by ZIKV, and therefore is
able to generate a protective ISG mediated response [3, 83, 93]. Data from the
deer mouse primary cell cultures indicate the potential for development as a
novel non-pathogenic model for ZIKV and Syrian golden hamsters as disease
models. Interestingly, the data yielded from the Jamaican fruit bat primary cell
cultures does not clearly indicate the category of ZIKV animal model that the bats
would fall in. Future research further investigating the expression levels of
different transduction protein genes along the signaling pathway and other ISGs
of the Type I IFN response during ZIKV infection with qPCR and deep seq RNA
analysis would be beneficial to confirm these findings and provide more insight
into the immune response pathway for all three animals. As well, examining the
phosphorylation levels of STAT1 and STAT2 with Western Blot assays in ZIKV
treated primary cell lines from Syrian golden hamsters and Jamaican fruit bats
would provide the necessary insight to determine if either of the species STAT
proteins are suppressed by the ZIKV NS5 in the same manner as humans. In
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alignment with the long term goals of this pilot study, results indicate that the
three compared species could be used for future development of effective
therapeutic treatments and vaccine research.
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APPENDIX A
LIST OF ACRONYMS
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Note: Acronyms and their definitions are listed out in the order they are
encountered within the text.
ZIKV: Zika virus
GBS: Gullian Barré syndrome
CZS: Congenital Zika virus syndrome
IFN: Interferon
Arboviruses: Athropod-borne viruses
YFV: Yellow fever virus
JEV: Japanese encephalitis virus
TBEV: Tick-borne encephalitis virus
WNV: West Nile virus
RNA: Ribonucleic acid
GAGs: Glycosaminoglycans
E protein: Envelope protein
C: Capsid protein
PrM: Pre-membrane protein
M: Membrane protein
RLR’s: Retinoic acid-inducible gene-I-like receptors
DNA: Deoxyribonucleic acid
mRNA: Messenger ribonucleic acid
RT-qPCR: Reverse transcriptase-quantitative polymerase chain reaction
DC: Dendritic cells
HUVEC: Human vascular endothelial cells
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MOIs: Multiplicity of Infections
PAMPS: Pathogen associated molecular patterns
PRRs: Pattern recognition receptors
MAVS: Mitochondrial antiviral signaling adapter
TBK1: Tank Binding Kinase 1
ISRE: IFN-stimulated response elements
ISG: Interferon stimulated genes
sfRNA: Subgenomic flaviviral RNA
PARP: Poly ADP ribose polymerase
LGTV: Langat virus
SPOV: Spondweni virus
PCR: Polymerase Chain Reaction
MODV: Modoc virus
SLEV: St. Louis encephalitis virus
PFU: Plaque forming unit
PRNT: Plaque reduction neutralization test
SQ: Subcutaneous
IP: Intraperitoneal
SOP: Standard operating procedure
PC: Pulmonary cell
DMEM: Dulbecco’s Modified Eagle Medium
DPBS: Dulbecco’s phosphate-buffered saline
FBS: Fetal bovine serum
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hpi: Hours post infection
TCID50: Tissue culture infectious dose 50
CPE: Cytopathic effect
ANOVA: Analysis of variance
PulV: Pulau virus
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APPENDIX B
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE APPROVAL
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Note: Prior to any work, all animals were euthanized per colony protocols and
none of the thesis work was done on live animal models. Therefore, no additional
protocols were necessary. The ARF has a colony protocol for bats and a holding
protocol was used briefly for the hamsters. The Hawkinson lab has a lab protocol
for deer mice (1109B-AH-DM-14) that is listed on the proceeding pages.
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IACUC Memorandum
To:

Dr. Ann Hawkinson

From: Laura Martin, Director of Compliance and Operations
CC:

IACUC Files

Date:

3/4/16

Re:

IACUC Protocol 1502B-AH-DM-18 Annual Renewal Approval

The UNC IACUC has reviewed your annual renewal request for animal use protocol 1502B-AH-DM18.
The committee’s review was based on the requirements of the Government Principles, the Public Health
Policy, the USDA Animal Welfare Act and Regulations, and the Guide for the Care and Use of
Laboratory Animals, as well as university policies and procedures related to the care and use of live
vertebrate animals at the University of Northern Colorado.
Based on the review, the IACUC has determined that all review criteria have been adequately addressed.
The PI/PD is approved to perform the experiments or procedures as described in the identified protocol
for an additional year.
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